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Abstract 
Pregabalin is an anticonvulsant agent used for the peripheral and central neuropathic pain 
treatment, marketed as Capsule and Solution dosage forms. The purpose of this study is to 
develop an immediate release Pregabalin Tablet, as a new dosage form in the Palestinian 
market that is bioequivalent to the FDA approved Reference Pregabalin Capsules (Lyrica).  
Pregabalin drug substance and the finished product during the time of development were 
not described in either the British or US pharmacopoeia.  
The chemical and physical evaluation of bulk drug substance (Pregabalin) was 
accomplished following the manufacturer`s analytical method and specification.  A new 
reversed-phase, isocratic LC method was developed and validated according to USP 
validation parameters, for the qualitative and quantitative determination of Pregabalin in 
pharmaceutical dosage forms using HPLC (LaChrome Elite) equipped with photodiode 
array UV detector. Mobile Phase is a mixture of Phosphate Buffer pH 6.9, and acetonitrile 
(94:6). 
Chromatographic System is Column: C-18 ODS 5 to 10µm in diameter (25cm X 4.6 mm 
id), detector: UV set at wavelength 210 nm, Flowrate: 1.5 ml / min and Injection Volume: 
20 μL.  
Formula development was accomplished through a series of steps:  
Selection of excipients through compatibility studies, selection of manufacturing process 
and in-vitro comparison studies versus the reference product.  
Excipients compatibilities were studied by preparing a binary mixture of Pregabalin and 
excipient (1:1) then sealed in neutral glass vials and incubated at 40±2 °C/75 ±5% RH for 
30 days. The mixtures were tested by means of FTIR for any possible interactions. The 
following excipients (Microcrystalline Cellulose, Pregelatinized Starch, Talc and Mg 
Stearate) were found to be compatible with Pregabalin. 
A series of pre formulation trials were composed and processed by direct compression 
method. Selection of formula was based on: 
Powder characteristics: (such as compressibility ratio, flowability, bulk density and tapped 
density), which would allow for a simplified method of manufacture, friability, hardness 
and disintegration of compressed tablets. 
The selected formulation was applied to prepare Pregabalin Tablets in two strengths, i.e. 
tablets containing 75mg/tablet and 300mg/tablet. They are prepared as dose weight 
proportional.  The compressed tablets were film-coated with PVA based polymer by using 
water as solvent. 
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The stability of film coated Pregabalin tablets were tested by incubating the finished 
products in their final package (PVC-Alum) at different storage conditions i.e. 25 ± 2 °C / 
60 % ±  5% RH, 30 C ±  2 °C / 60% ±  5% RH and 40 C ±  2 °C / 75% ±  5% RH. Samples 
were tested biweekly for content of Pregabalin (assay), physical appearance, dissolution 
rate, and degradation products. 
Pregabalin Tablets proved to be stable in all aspects for the period tested (1 month) at all 
storage conditions.  
Biowavier study was performed between Pregabalin Tablets (75mg and 300mg) and the 
Reference Pregabalin Capsules (Lyrica 75 and 300mg Capsules) using paddle method 
rotated at 50 rpm in different dissolution media (0.06N Hydrochloric acid solution, Acetate 
buffer pH 4.5 and phosphate buffer pH 6.8. It was found that either Reference or Test 
products release more than 85% of their Pregabalin content in 15 minutes. As Pregabalin 
API, according to BCS is Class I drug and the dissolution profiles of Pregabalin Tablets is 
similar to that of Reference Pregabalin Capsules (Lyrica) under the same test conditions, 
and all excipients used are not suspect of having any relevant impact on bioavailability it is 
strongly believed that the developed Pregabalin Tablets are bioequivalent to the marketed 
Lyrica Capsules. 
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Introduction 
1.1 Background information on Pregabalin  
Ref: {(1). (1) (2)} 
1.1.1 Description 
 Pregabalin is a white to off-white, crystalline solid powder and has Structural formula 
as shown in the next figure. 
 
Figure 1: Structure formula of Pregabalin 
 
 Chemical name:  (S)-3-(aminomethyl)-5-methylhexanoic acid.  
 The molecular formula is C8H17NO2  
Relative molecular mass is 159.23.   CAS: 148553-50-8 
 
1.1.2 General properties:  
 Solubility: Sparingly soluble in water 
 Melting point (DSC): About 196.67°C 
 Optical rotation[α] 23d (c = 1.06 in water):  +10.0° to +12.0° 
 Isomerism: Pregabalin contains one Chiral center in its structure and exist as S(+) and R(-) 
isomers. 
 Dissociation constants: pKa1 of 4.2 for carboxylic acid and pKa2 of 10.6 for amine moiety 
 Experimental Log P: 1.3, the log of the partition coefficient (n-octanol/0.05M phosphate 
buffer) at pH 7.4 is -1.35. 
 
1.1.3 Impurities:                                                                             [Ref Alembic DMF] 
 R-Isomer: NMT 0.15% 
 Impurity-III: ((R)-(-)-3-(Carbamoylmethyl)-5-methyl hexanoic acid (R-CMH): NMT 
0.15% w/w. 
 Impurity-IV: 2-Pyrrolidinone, 4-(2-methylpropyl): NMT 0.15% w/w). 
 Any other impurity: NMT 0.10% w/w. 
 Total impurities: NMT 0.50% w/w. 
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1.1.4 Pharmacokinetics 
Pregabalin steady-state pharmacokinetics is similar in healthy volunteers, patients with 
epilepsy receiving anti-epileptic drugs and patients with chronic pain. 
1.1.5 Absorption 
Pregabalin is rapidly absorbed when administered in the fasted state, with peak plasma 
concentrations occurring within 1 hour following both single and multiple dose 
administration. Pregabalin oral bioavailability is estimated to be ≥ 90% and is independent 
of dose. Following repeated administration, steady state is achieved within 24 to 48 hours. 
The rate of pregabalin absorption is decreased when given with food resulting in a decrease 
in Cmax by approximately 25-30% and a delay in Tmax to approximately 2.5 hours. However, 
administration of pregabalin with food has no clinically significant effect on the extent of 
pregabalin bioavailability. 
Pregabalin is well absorbed after oral administration, is eliminated largely by renal 
excretion, and has an elimination half-life of about 6 hours. 
1.1.6 Distribution 
In preclinical studies, Pregabalin has been shown to readily cross the blood brain barrier in 
mice, rats, and monkeys. Pregabalin has been shown to cross the placenta in rats and is 
present in the milk of lactating rats. In humans, the apparent volume of distribution of 
Pregabalin following oral administration is approximately 0.56 L/kg. Pregabalin is not 
bound to plasma proteins. At clinical doses of 150 to 600 mg/day, the average steady-state 
plasma Pregabalin concentrations were approximately 1.5 and 6.0 µg/mL, respectively. 
1.1.7 Indications and Clinical uses 
 Pregabalin is indicated for the treatment of neuropathic pain in adults. 
 Pregabalin is indicated as adjunctive therapy in adults with partial seizures with or 
without secondary generalization. 
Pregabalin is available in the market as immediate release Capsules and solution dosage 
forms. Pregabalin (LYRICA Capsules) are administered orally and are supplied as imprinted 
hard-shell Capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of Pregabalin and 
packaged in either HDPE bottles or PVC- Aluminum blisters, while Lyrica Oral solution 
contains 20mg/ml of Pregabalin. 
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1.2 Tablet: properties and manufacturing Techniques 
 
1.2.1 Tablet properties 
A tablet is a solid pharmaceutical dosage form that comprises a mixture of active substances 
and excipients, usually in powder form, pressed or compacted from a powder into a solid 
dose.  
API has to be in pure form otherwise impurities can catalyze series of chemical reactions. 
The API should be stable against photolysis, oxidation, hydrolysis, etc. to keep the 
formulation a simple one. Sensitive particles require careful handling during manufacturing. 
 
The excipients can include: 
1. Diluents, binders or granulating agents, glidants (flow aids) and lubricants to ensure 
efficient tableting. 
2. Disintegrants to promote tablet break-up in the digestive tract. 
3. Sweeteners or flavors to enhance taste in chewable tablets. 
4. Colors and pigments to make the tablets visually attractive. 
5. A polymer coating is often applied to make the tablet smoother and easier to swallow, to 
control the release rate of the active ingredient, to make it more resistant to the 
environment (extending its shelf life), or to enhance the tablet's appearance. 
The compressed tablet is the most popular dosage form in use today. About two-thirds of 
all prescriptions are dispensed as solid dosage forms, and half of these are compressed 
tablets. A tablet can be formulated to deliver an accurate dosage to a specific site; it is 
usually taken orally, but can be administered sublingually, buccally, rectally or intra-
vaginally.  
  
Tablet Requirements: 
6. Should be an elegant product having its own identity while being free of defects such as 
chips, cracks, discoloration, contamination, and the like. 
7. Should have the strength to withstand the rigors of mechanical socks encountered in its 
production, packaging, shipment, and dispensing 
8. Should have the chemical and physical stability to maintain its physical attributes over 
time. 
9. Must be able to release its active components in the body in a predictable and 
reproducible manner. 
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1.2.2 Tablet Manufacturing Techniques 
The manufacture of tablet dosage forms is a complex multi-stage process under which the 
starting materials change their physical characteristics a number of times before the final 
dosage form is produced. 
The main three manufacturing approaches are illustrated in the following flow charts 
(Figure 2): 
Weighing
Sifting
Dry mixing
Granulation
Screening of 
Damp mass
Material 
issuance &
Receiving
Drying 
Dry Screening
Lubricant 
Blending
Compression
Blistering
Weighing
Sifting
Dry mixing
Slugging/
Compaction
Material 
issuance &
Receiving
Dry Screening
Lubricant 
Blending
Compression
Weighing
Sifting
Dry mixing
Material 
issuance &
Receiving
Lubricant 
Blending
Compression
Final 
Packaging
 Tablet processing technologies
Dry 
Granulation
Direct 
Compression
Wet 
Granulation
Binder 
Solution
Coating
Blistering
Final 
Packaging
Coating
Blistering
Final 
Packaging
Coating
 
 Figure 2: Manufacturing process flowchart 
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A. Direct compression  
Direct compression consists of compressing tablets directly from powdered materials without 
modifying physical nature of materials. This method is applicable for crystalline chemicals having 
good compressible characteristic and flow properties. 
If the bulk powder blend's properties do not suit direct compression Tableting, manufacturers will 
turn to granulation processes to create the desired flowability and low dust ability. These 
characteristics are required to minimize tablet weight variations and ensure high density for high 
tablet filling weight and high mold ability for hard tablet manufacture. 
B. Dry granulation 
Dry granulation method is defined as the formation of granules by slugging or compaction, if the 
Tableting ingredients are sensitive to moisture and/or unable to withstand elevated temperature 
during drying. 
C. Wet granulation 
Wet granulation forms the granules by binding the powders together with an adhesive, instead of 
by slugging or compaction. 
 
1.3 Raw Materials (Excipients) 
Excipients are the components of a finished drug product other than the active 
pharmaceutical ingredient (API) and are added during formulation for a specific purpose. 
Criteria for Excipients selection 
1. They should be nontoxic and acceptable to the regulatory agencies in all countries 
where the product is to be marketed. 
2. They must be commercially available in an acceptable grade in all countries where the 
product is to be manufactured. 
3. Their cost must be acceptably low. 
4. They must not be contraindicated by themselves or because of a component (e.g., 
Sodium) in any segment of the population. 
5. They must be physiologically inert. 
6. They must be physically and chemically stable by themselves and in combination with 
the drug(s) and other tablet components. 
7. They must be free of any unacceptable microbiologic “load”. 
8. They must be color- compatible (not produce any off-color appearance) . 
9. If the drug product is also classified as a food, the excipients must be approved direct 
food additives. 
10. They must have no deleterious effect on the bioavailability of the drug(s) in the 
product. 
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Types of Excipients                                                                                            [Ref. (3)] 
A. Diluents (Or Fillers): Diluents increase the volume to a formulation to prepare tablets 
of the desired size. Widely used fillers are lactose, microcrystalline cellulose (Avicel 
PH® from FMC Corp. and Emococel® from Mendell), starch and pregelatinized starch; 
the filler is selected based on various factors, such as the cost, and compatibility with 
other formulation ingredients.  
B. Binders (Or Adhesives): Binders promote the adhesion of particles of the formulation. 
Such adhesion enables preparation of granules and maintains the integrity of the final 
tablet. Starch and pregelatinized starch are commonly used as binding agents. 
C. Lubricants: Lubricant is a substance capable of reducing or preventing friction, heat, 
and wear when introduced as a film between solid surfaces. It works by coating on the 
surface of particles, and thus preventing adhesion of the tablet material to the dies and 
punches. Magnesium Stearate is one example of a lubricant.  
 
In addition lubricants play other roles in the preparation of tablets such as:  
 
• Improve the flow of granules in the hopper to the die cavity.  
• Reduce the friction between the tablet and the die wall during the tablet’s ejection 
from the tablet machine.  
• Give sheen to the finished tablets. 
 
D. Glidant: Substance that allows particles moving smoothly and continuously. Glidant 
works by removing moisture and as a result enhancing flow. Talc has both lubricant and 
glidant effects. 
E. Disintegrators (Or Disintegrating Agents): To rupture or breakup of tablets, 
disintegrating agents must swell or expand on exposure to aqueous solution. Thus, the 
most effective disintegrating agents in most tablet systems are those with the highest 
water uptake property. In general, the more hydrophilic, the better disintegrating agents 
are therefore highly hydrophilic, e.g. Microcrystalline cellulose. 
Microcrystalline cellulose has various functions in direct compression. It can be used as 
a binder, disintegrant, and filler. Microcrystalline cellulose allows direct compression of 
tablets and wet granulation processes.  
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F. Coating Material: 
[Ref. (4)] 
The coating is being applied to a dosage form for a purpose ranging from the esthetic to 
a desire to control the Absorption of the drugs. The major components of film coating 
formulation consist of a polymer, plasticizer, colorant and solvent, Cellulose ether such 
as Hydroxypropyl methylcellulose (HPMC) and polyvinyl alcohol (PVA) are often the 
preferred polymers in film coating. 
The major solvent used in film coating typically alcohols and purified water. 
1.4 Packaging Material                                                                       
 [Ref. (5) (6) (7)] 
Packaging process is defined as the collection of different components which surround the 
pharmaceutical product from the time of production until its use. 
FDA definition "A container closure system refers to the sum of packaging components that 
together contain and protect the dosage form. This includes primary packaging components 
and secondary packaging components, if the latter are intended to provide additional 
protection to the drug product. A packaging system is equivalent to a container closure 
system". 
A primary packaging component means a packaging component that is or may be in direct 
contact with the dosage form. A secondary packaging component means a packaging 
component that is not and will not be in direct contact with the dosage form. 
                                Figure 3: Blister packaging for Pregabalin tablets after blistering stage 
1.4.1 Selection of packaging material dependent on several parameters: 
 Moisture barrier requirements. 
 Light barrier requirements. 
 Gas barrier requirements. 
 Chemical properties. 
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1.4.2 Importance of packaging  
Blister packaging is becoming more accepted for the manufacturers and consumers 
recognize its benefits. Blister packs can help patients follow drug regimens, protect drugs 
over a long shelf life, and are portable. Many aspects in blister packaging is better than 
conventional packaging.  
 
a. Product integrity 
Blister packaging helps retain product integrity because drugs that are prepackaged in 
blisters are shielded from adverse conditions. Furthermore, opportunities for product 
contamination are minimal, and each dose is identified by product name, lot number, 
and expiration date. Therefore, blister packaging ensures product integrity from the 
producer directly through distribution to the consumer.  
 
b. Product protection 
Blister packaging, however, keeps each tablet or capsule hermetically sealed in its own 
bubble. Drugs that are not taken remain in the original package and are fully protected 
against external conditions. A blister protects a moisture sensitive tablet right up to 
administration. In contrast, the moisture in the headspace of a multiple-unit bottle is 
replaced each time the bottle is opened.  
Table 1 illustrates the different polymers used in packaging and their properties. 
Table 1: Comparison of forming films                                                                                          
 [Ref. (8)] 
Type and Thickness of Forming 
Film 
WVTR 
(g.mil/100in
2
/day) 
@ 100°F and 90% RH 
OTR 
(cc.mil/100in
2
/day) 
@ 77°F 
Cold form foil 0.00 0.00 
Polycholorotrifluror ethylene 
(PCTEF) 
0.016 7.0 
Polyvinyl dichloride (PVDC) 0.1-0.2* 0.15-0.9 
High density polyethylene 0.3-0.4 139-150 
Polypropylene (PP) 0.69-1.0 182 
Low density polyethylene (LDPE) 1.2-2.0 3-5 
Poly ethylene terephthalate (PET) 1.2-2.0 3-5 
Poly vinyl chloride 0.9-5.1 5-20 
Ethylene vinyl alcohol (EVOH) 1.4-5.4* 0.05-0.90 
Polystyrene  (PS) 7-10 350-400 
Nylon 16-20 1.0 
* As measured on the unformed film at an ambient temperature of 104°F and 90% RH 
 
c. Tamper evidence 
Tamper evidence is strength of blister packaging. The dosage units are individually 
sealed in constructions of plastic, foil, and/or paper. The package must be designed so 
that one must tear the compartment to get at the product, and it must not be possible to 
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separate the backing materials from the blister without leaving evidence. Once a bottle 
has been opened, whatever tamper-evident mechanism it had is gone. With blister 
packaging, however, each tablet or capsule is individually protected from tampering 
until use, so any form of tampering with a blister package is immediately visible. 
  
d. Other advantage as: 
 Reduced possibility of accidental misuse as Child resistance. 
 Patient compliance and Carry the correct information and identification of the 
product.  
 
1.4.3 Blister packaging components 
The four basic components of pharmaceutical blister packages as illustrated in Figure 4. 
 The forming film. 
 The lidding material. 
 The heat-seal coating. 
 The printing ink. 
 
Forming films account for approximately 80–85% of the blister package, and lidding 
materials make up 15–20% of the total weight of the package. Because the forming film and 
the lidding material form an integrated package, they must match precisely.  
 
 Figure 4: Basic components of blister packaging. 
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1.4.3.1 Forming film 
The forming film is the packaging component that receives the product in deep drawn 
pockets. One key to package success is selecting the right plastic film for the blisters in 
terms of its property type, grade, and thickness. Consideration must be given to the height 
and weight of the product, sharp or pointed edges of the final package, and the impact 
resistance, aging, migration, and cost of the film. The plastic also must be compatible with 
the product. Factors influencing package production and speed of assembly must be taken 
into account, including heat sealing properties and the ease of cutting and trimming formed 
blisters. 
Plastic forming films such as PVC, polypropylene (PP), and polyester (PET) can be 
thermoformed, but support materials containing aluminum are cold-formed. The forming 
film usually is colorless and transparent, but it can be obscured for use in child resistant 
packages or to protect light sensitive drugs. The forming web for blister packs nearly always 
is PVC, sometimes coated or laminated with additional components that enhance the oxygen 
and water-vapor barrier. 
 
Types of forming films 
PVC forming film is called rigid PVC because it is almost free of softening agents. Rigid 
PVC is a very clear, stiff material with a low WVTR. It exhibits excellent thermoform 
ability; a high flexural strength; good chemical resistance; low permeability to oils, fats, and 
flavoring ingredients; easy tintability; and low cost. These properties make rigid PVC the 
material of choice for blister packaging, and it essentially has 100% of the market for the 
plastic component. PVC films that are thermoformed have a thickness of about 10 mil.  
The use of PVC has attracted much criticism because its combustion produces hydrochloride 
emissions, where many pharmaceutical companies now stipulate that any new blister 
machines must be capable of handling both PVC and PP.  
 
a. Polyvinylidene chloride (PVDC)–coated PVC 
Although its volume in drug packaging is small, PVDC plays a critical role in blister 
packaging as laminations or coatings on PVC. PVDC is the most common coating in 
blister packaging because it can reduce the gas and moisture permeability of PVC 
blister packages by a factor of 5–10. Coated PVC films have a thickness of 8–10 mil; 
the thickness of the PVDC coat amounts to 1–2 mil. The coating is applied on one 
side and usually faces the product and the lidding material.  
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b. PVC/Chlorotrifluoroethylene (CTFE) 
Films made from PVC and CTFE have the lowest water-vapor permeability of all 
films used for blister packaging. When compared with the water-vapor permeability 
of 10-mil PVC, the permeability of 8-mil PVC/0.76- mil CTFE is lower by a factor 
of 15. However, the environmental concerns regarding PVC also apply to 
PVC/CTFE films. 
  
c. Polypropylene (PP) 
There is an increasing trend toward using PP as a support material for blister 
packages. The water-vapor permeability of uncoated PP is lower than that of PVC 
and is comparable to that of PVDC-coated PVC. The thickness of PP films used in 
the thermoforming process ranges from 10 to 12 mil. Advantages of PP include easy 
recyclability, no release of toxins during incineration, and good moisture-barrier 
properties. PP is a possible replacement for PVC, especially in Europe. However, the 
use of PP has its drawbacks. One problem is thermoforming. The temperatures 
required for thermoforming PP and for the subsequent cooling process must be 
controlled precisely. Warping also can occur, Other difficulties associated with the 
use of PP include its thermal instability, higher rigidity than PVC, and susceptibility 
to post-processing shrinkage. In addition, PP is difficult to run on a standard blister 
machine and cannot be processed as fast as PVC. If a company runs PP and needs 
new equipment, it must go through a precise validation process, performing various 
tests on PP to satisfy FDA requirements.  
 
d. Polyethylene terephthalate (PET) 
PET is another material that may replace PVC, but its relatively high water-vapor 
permeability compared with that of PVC will prevent its universal use. PVDC coated 
PET could have the same water vapor barrier effect as PVC, but this does not appear 
to be promising in view of the larger goal to replace chlorous plastics with PET. 
 
e. Polystyrene (PS)  
Polystyrene (PS) is perfectly compatible with thermoforming, but its high water 
vapor permeability makes it unsuitable as a blister material for pharmaceutical 
purposes. 
 
f. Oriented polyamide (OPA)/aluminum/PVC or nylon/aluminum/PVC 
OPA/aluminum/PVC laminates are intriguing. With a laminate structure consisting 
of 1-mil OPA, 1.8- mil aluminum, and 2.4-mil PVC it is possible to eliminate water-
vapor permeability almost entirely.  
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1.4.3.2 Lidding materials  
The lidding material provides the base or main structural component upon which the final 
blister package is built. It must be selected according to the size, shape, and weight of the 
product as well as the style of the package to be produced. Lidding materials range in caliper 
or thickness from 0.36 to 0.76 mm, but 0.46–0.61 mm is the most popular range. The 
surface of the lidding material must be compatible with the heat-seal coating process. Clay 
coatings are added to the lidding material to enhance printing. Heat-sealing and printability 
are both important considerations in blister packaging, and the lidding material must offer 
the best workable compromise.  
 
 Characteristics  
The lidding material can be clear plastic, but in pharmaceutical packaging it is either 
plain or printed 1- mil foil (for push-through blister types) or paper/foil or 
paper/PET/foil laminations (for child-resistant peel–push types). The lidding 
material must guarantee a WVTR that is at least as low as that of the forming films, 
and it must be suitable for the type of opening appropriate to the package (e.g., push-
through or peel-off). Figure 5 shows a cross-section of a peel off–push through 
lidding material.  
 
Figure 5: Cross section of a peel off–push through lidding material. 
 
Table 2: Different types of lidding materials 
Type and Thickness of Lidding material (mil) 
Weight 
(g/m2) 
0.8-mil Aluminum, hard, push-through 60 
0.8-mil Aluminum, hard, heat seal–coated, side-printed, push-through 61 
1-mil Aluminum, soft, child resistant 76 
45 g(m22)/1-mil Paper/aluminum, peel-off 171 
45 g(m22)/0.48-mil Paper/PET/aluminum, peel off–push through 142 
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 Types of lidding materials 
Hard aluminum is the most widely used push-through lidding material in Europe. 
The foil usually has a thickness of 0.8ml, other type of lidding material Soft 
aluminum (1 ml) frequently is used for child-resistant push-through foils. With the 
exception of the type of aluminum used, the structure of this lidding material 
corresponds to that of hard aluminum (0.8 ml). The softness and thickness of this 
type of aluminum help prevent children from pushing tablets through it.  
And there is Paper/aluminum In combinations of paper and aluminum, and there is  
Paper/PET/aluminum. Lidding material made of a paper/PET/aluminum laminate is 
often called peel off–push through foil. 
 
1.4.3.3 Printing inks  
Printing inks provide graphics and aesthetic appeal. They can be applied to the lidding 
material by letterpress, gravure, offset, flexographic, or silk-screen printing processes. 
Printing inks must resist heat sealing temperatures as high as 300°C without showing any 
discoloration or tackiness (blocking). In addition, they must sufficiently resist abrasion, 
bending, and fading and must be safe for use with the intended product. Printing inks should 
not contain excessive amounts of hydrocarbon lubricants, greases, oils, or release agents. 
Qualification tests should always precede production runs. Finally, printing inks must 
comply with FDA recommendations. 
 
 
1.5 Tablets Quality  
[Ref. (9)] 
ICH Guidance Q6A and USP General Chapter 2, have a recommendation and specification 
to ensure that tablets are safe and effective at the time of release and over their shelf life.  
Drug product quality test for oral drug product fall into two categories: universal tests that 
are applicable to all oral drug products and specific tests that should be considered for 
inclusion for specific types of oral products. 
Tests that are universally applied to ensure safety, efficacy and quality include description, 
identification, assay-strength, and impurities (organic, inorganic and residual solvents). 
Specific tests for tablets include disintegration, friability, breaking force-hardness, 
uniformity of dosage unit and dissolution. 
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1.5.1 Description 
It is general in nature and not standard in itself. It communicates the general appearance 
(color, shape, diameter, thickness and surface) of the formulated tablets that are inspected 
and tested visually, while the dimensions were measured by using a suitable caliper. 
1.5.2 Identification: 
It is an aid to confirm that the drug product contains the labeled drug substance by providing 
a positive identification of the drug substances in the drug produced. 
1.5.3 Assay 
It is a specific and stability-indicating test to determine the content (potency) of the drug 
product. In most cases a prior acceptable of ±10% variation in limits of assay from the target 
(label claim 100%) is accepted Acceptance criteria of 95.0%-105.0% are used for drug 
product with narrow therapeutic index. 
1.5.4 Impurities: 
During product manufacture and over the shelf-life of the product, degradation product can 
form, as a result of degradation of the drug substance and excipients.  
The procedure and acceptance criteria should specifically limit toxic material. 
1.5.5 Hardness 
It is the force required to cause the tablet break in a specific plane, tablet hardness or 
breaking force is measured by placing the tablet between two platens of the hardness tester, 
one of which moves to apply sufficient force to the tablet to cause fracture.  
 
 
Figure 6: Hardness Tester 
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1.5.6 Friability [Ref. (10)]: 
It is generally run once and applicable to most compressed non coated tablet. It is percentage 
weight loss after testing the tablet in a drum rotated 100 times. 
 
Figure 
7: 
Friability Tester 
Acceptance Criteria: maximum mean weight loss from the three samples of not more 
than1.0% is considered acceptable for most products. 
 
1.5.7 Disintegration Test [ref. (11)]: 
To test for disintegration time, one tablet is placed in each tube and the basket rack is 
positioned in a 1-L beaker of water at 37 ± 2.0 C such that the tablet remain 2.5 cm below 
the surface of liquid on their upward movement and not closer than 2.5 cm from the bottom 
of the beaker in their downward movement. Move the basket containing the tablets up and 
down through a distance of 5-6 cm at a frequency of 28 to 32 cycles per minute. According 
to the test the tablet must disintegrate and all particles must pass through the 10 mesh screen 
in the time specified. If any residue remains, it must have a soft mass.  
 
 
Figure 8: Disintegration apparatus. (All dimensions are expressed in mm.) 
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1.5.8 The Uniformity of dosage Unit                                                                  [Ref. (12)] 
The term “uniformity of dosage unit” is defined as the degree of uniformity in the amount of 
the drug substance among dosage units. Each unit in a batch should have a drug substance 
content within a narrow range around the label claim (consistency of dosage units). 
The uniformity of dosage units can be demonstrated by unit-dose either of two methods, 
Content Uniformity or Weight Variation and that depend on the weight of active ingredient 
(Dose) and the percent of label claim (ratio of drug Substance) according to the table 3: 
Table 3: Application of Content Uniformity (CU) and 
Weight Variation (WV) Tests for Dosage Forms 
 
a. In case of Weight Variation 
The assay for the drug substance(s) on a representative sample of the batch using an 
appropriate analytical method is carried out. This value is expressed as percent of 
label claim. Assuming that the concentration (weight of drug substance per weight of 
dosage unit) is uniform, not fewer than 30 dosage units, For uncoated or Film Coated 
Tablets are selected, and 10 units are accurately weighted individually and the 
content, expressed as % of label claim, of each tablet from the weight of the 
individual table is calculated and the acceptance value from the result of the Assay is 
calculated According to USP, Chapter <905>. 
b. In Case of Content Uniformity 
Select not fewer than 30 units, and assay 10 units individually using an appropriate 
analytical method, calculate the acceptance value, the content uniformity procedures 
for all different dosage forms are found in the USP Chapter <905>. 
 
1.5.9 Dissolution for routine testing: 
[Ref (13)] 
The pharmaceutical scientist would like to find a relationship between an in vitro 
characteristic of a dosage form, and it’s in vivo performance. 
Disintegration was originally thought to be this characteristic.  The USP introduced its 
disintegration test in 1950. 
With advances in methodology, the disintegration test was found to be too insensitive, and 
dissolution test methods were introduced in the USP in 1968. 
Dissolution is principally useful as a QC test.  It can be predictive of in vivo behavior. 
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1.6 Compatibility Study                                                                          
                                                                                                                                                [Ref (14)] 
The drug-excipient compatibility studies are the first step for dosage form development in 
the pre-formulation stages of the development of a dosage form. The potential physical and 
chemical interactions between drugs and excipients can affect the chemical, physical and 
therapeutically properties and stability of the dosage form. 
Physical interactions are common in dosage form and also difficult to detect. Physical 
interactions may or may not involve chemical changes, but may change dissolution, 
solubility, adsorption, solid dispersion complexation and other properties. 
 
Chemical Interactions involve the reaction of API’s and excipients to form unstable 
compounds that have a deleterious effect on the formulation. 
Biopharmaceutical interaction are observed after administration of the medication, Some 
excipients may interact in physiological way when they are administration along with API’s 
causing changes such as premature breakdown of enteric coat, increase in gastrointestinal 
motility. 
Methods of estimation of drug excipient compatibility include thermal such as DSC, TEA, 
DTA and hot stage microscopy) and non-thermal analytical techniques as Vibrational 
spectroscopy, Powder X-ray diffraction and solid state NMR. 
The samples for binary Mix Compatibility Testing are prepared by triturating API with the 
individual excipient as 1:1 powder mixes, stored under accelerated conditions as powder 
mixes or slurries in water; then analyzed by stability-indicating methodology, e.g. HPLC, 
FTIR. 
   
 
Figure 9: FTIR Spectrophotometry used in analysis compatibility study samples 
 
  
19 
 
1.7 Bioequivalence & Biowaiver Study 
 [Ref. (15), (16) (17)] 
1.7.1 Background  
In 1995 the American Department of Health and Human Services, US Food and Drug 
Administration (HHS-FDA) instigated the Bio-pharmaceutics Classification System (BCS), 
with the aim of granting so-called biowaivers for scale-up and post-approval changes 
(SUPAC).           (www.fda.gov/cder/ guidance/cmc5.pdf)  
A Biowaiver means that in vivo bioavailability and/or bioequivalence studies may be 
waived (i.e. not considered necessary for product approval). Instead of conducting expensive 
and time-consuming in vivo studies, a dissolution test could be adopted as the surrogate 
basis for the decision as to whether two pharmaceutical products are equivalent. At that time 
the biowaiver was only considered for SUPAC to pharmaceutical products. 
More recently, the application of the biowaiver concept has been extended to approval of 
certain orally administered generic products. 
(www.fda.gov/cder/guidance/3618fnl.htm) 
Only APIs with high solubility and high permeability and which are formulated in solid, 
immediate release (IR) oral formulations can be approved on the basis of the biowaiver 
procedure. A major advantage of the biowaiver procedure is the simplification of the 
product approval process and the reduction of the time required, thus reducing the cost of 
bringing new products to market.  
 
1.7.2 Biowaiver Study and Biopharmaceutics Classification System (BCS) 
The BCS is a scientific framework for classifying drug substances based on their aqueous 
solubility and intestinal permeability.  When combined with the dissolution of the drug 
product, the BCS takes into account three major factors that govern the rate and extent of 
drug absorption from IR solid oral dosage forms:  (1) dissolution, (2) solubility, and (3) 
intestinal permeability. 
According to the BCS, drug substances are classified as follows:  
Class 1:  High Solubility – High Permeability  
Class 2:  Low Solubility – High Permeability  
Class 3:  High Solubility – Low Permeability  
Class 4:  Low Solubility – Low Permeability 
 
Depending on the classification, the oral availability of the API may be expected to range 
from being heavily dependent on the formulation and manufacturing method (e.g. Class II 
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APIs: poorly soluble yet highly permeable) to being mostly dependent on the API 
permeability properties (e.g. Class III APIs: highly soluble yet poorly permeable). 
The next diagrams depicting the products eligible for the biowaiver procedure under the 
HHS-FDA guidance and those eligible according to the WHO are presented in Fig. 10 and 
Fig. 11, respectively. 
 
Figure 10: products eligible for the biowaiver procedure under the HHS-FDA guidance 
 
Figure 11: products eligible for the biowaiver procedure under the WHO guidance 
 
1.7.3 Solubility Definitions 
A. Solubility FDA definitions 
The aqueous solubility of a drug substance is considered as high according to the 
HHS-FDA BCS criteria when: 
• the ratio of the highest orally administered dose (in mg) to the solubility (mg/ml) 
is 250 ml or lower over the pH range 1–7.5 at 37 °C. 
According to HHS-FDA guidance, the determination of the equilibrium solubility 
is carried out with the shake-flask method (other methods such as acid or base 
titration are permitted when their ability to predict the equilibrium solubility is 
justified). The experiments should be carried out in triplicates at a temperature of 
37± 1°C. at a number of pH conditions chosen to cover the pH range of 1–7.5. 
The buffer solutions given in the United States Pharmacopeia (USP) are 
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appropriate for the tests, but other buffers are also allowed for these experiments. 
The pH value of each buffer solution should be checked before and after each 
experiment. Degradation of the API due to pH or buffer composition should be 
reported together with other stability data. 
The reason for the 250-ml cut-off criterion for the dose: solubility ratio is that in 
pharmacokinetic bioequivalence studies, the API formulation is to be ingested 
with a large glass of water (8 ounces corresponds to about 250 ml). If the highest 
orally administered dose can be completely dissolved in this amount of water, 
independent of the physiological pH value (hence the determination over the pH 
range 1–7.5), solubility problems are not expected to hinder the uptake of the API 
in the small intestine. 
B. Solubility WHO definition 
When an API shows a dose: solubility ratio of 250 ml or lower at 37°C over a pH 
range of 1.2–6.8, it can be classified as “highly soluble”. The decrease in pH from 
7.5 in the FDA guidance to 6.8 reflects the need to dissolve the drug before it 
reaches the mid-jejunum to ensure absorption from the gastrointestinal tract. 
• Furthermore, the dose that is to be used for the calculation is the highest dose 
indicated in the Model List of Essential Medicines (EML). 
C. Solubility EMA definition 
The pH-solubility profile of the drug substance should be determined and 
discussed. The drug substance is considered highly soluble if the highest single 
dose administered as immediate release formulation(s) is completely dissolved in 
250 ml of buffers within the range of pH 1 – 6.8 at 37±1 °C. This demonstration 
requires the investigation in at least three buffers within this range (preferably at 
pH 1.2, 4.5 and 6.8) and in addition at the pKa, if it is within the specified pH 
range. Replicate determinations at each pH condition may be necessary to achieve 
an unequivocal solubility classification (e.g. shake-flask method or other justified 
method). Solution pH should be verified prior and after addition of the drug 
substance to a buffer. 
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1.7.4 Permeability definition 
A. Permeability FDA definition 
The other important parameter for the BCS is the intestinal permeability of the API. 
According to HHS-FDA a drug is considered highly permeable, when 90 % or more 
of the orally administered dose is absorbed in the small intestine. 
Permeability can be assessed by pharmacokinetic studies (for example, mass balance 
studies), or intestinal permeability methods, e.g. intestinal perfusion in humans, 
animal models, Caco 2 cell lines or other suitable, validated cell lines. In vivo or in 
situ animal models or in vitro models (cell lines) are only considered appropriate by 
HHS-FDA for passively transported drugs. It should be noted that all of these 
measurements assess the fraction absorbed (as opposed to the bioavailability, which 
can be reduced substantially by first-pass metabolism). 
HHS-FDA suggests use of two different methods for determining the permeability 
classification if results with one method are inconclusive. 
B. Permeability WHO definition 
When an API is absorbed to an extent of 85% or more, it is considered to be “highly 
permeable”. The permeability criterion was relaxed from 90% in the FDA guidance 
to 85% in the WHO “Multisource document”. 
C. Permeability EMA definition 
The demonstration of complete absorption in humans is preferred for BCS-based 
biowaiver applications. For this purpose, complete absorption is considered to be 
established where measured extent of absorption is ≥ 85 %. Complete absorption is 
generally related to high permeability. 
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1.7.5 Biowaiver Study Requirements 
A. Biowaiver Study / FDA Requirements 
To be considered bioequivalent according to the HHS-FDA biowaiver procedure, a 
pharmaceutical product: 
a) Should contain a Class I API. 
b) Should be rapidly dissolving, meaning it should release at least 85% of its 
content in 30 minutes in three different media (pH 1.2, pH 4.5 and pH 6.8, in a 
paddle (50 rpm) or basket (100 rpm) apparatus at 37 °C and a volume of 900 
ml. 
c) Should not contain excipients which could influence the absorption of the API. 
d) Should not contain an API with a narrow therapeutic index. 
e) Should not be designed to be absorbed from the oral cavity. 
The reasoning for the above-mentioned dissolution restrictions is that when a highly 
soluble, highly permeable API dissolves rapidly, it behaves like a solution in the 
gastrointestinal tract. If this is the case, the pharmaceutical composition of the 
product is insignificant, provided that excipients which influence the uptake across 
the gut wall are excluded from the formulation. 
The API is not prone to precipitation after its dissolution due to its good solubility 
under all pH conditions likely to be found in the upper gastrointestinal tract. The 
high permeability ensures the complete uptake (> 90%) of the API during its 
passage through the small intestine. The rapid dissolution of the product guarantees 
that the API is available long enough for the uptake in the small intestine (the 
passage time in the small intestine is approximately four hours) and negates any 
slight differences between the formulations. 
Pharmaceutical products containing an API with a narrow therapeutic index should 
always be tested with in vivo methods, because the risk to the patient resulting from 
a possible incorrect bioequivalence decision using the biowaiver procedure is 
considered too high with these kinds of APIs. 
As the BCS is only applicable to APIs which are absorbed from the small intestine; 
drugs absorbed from other sites (e.g. from the oral cavity) are not eligible for a 
biowaiver. 
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B. Biowaiver Study / WHO Requirements  
In the “Multisource document”,1 the WHO has broadened the scope of application 
of the biowaiver in three directions: 
(1) The criteria for classification as a Class I API have been relaxed with respect to 
both the dose: solubility ratio and permeability requirements. 
(2) The new requirements allow pharmaceutical products containing Class III APIs 
to be considered for a biowaiver, under application of more stringent dissolution 
criteria. 
(3) The document further allows pharmaceutical products containing BCS Class II 
APIs that are weak acids which have a dose: solubility ratio of 250 ml or less at pH 
6.8 to be eligible for the biowaiver procedure, provided that they dissolve rapidly at 
pH 6.8 and similarly to the comparator product at pH 1.2 and 4.5. 
C. Biowaiver Study Requirements According to EMA 
BCS-based biowaiver are applicable for an immediate release drug product if  
 the drug substance has been proven to exhibit high solubility and complete 
absorption (BCS class I; for details see section III) and either very rapid (> 85 % 
within 15 min) or similarly rapid (85 % within 30 min) in vitro dissolution 
characteristics of the test and reference product has been demonstrated 
considering specific requirements.  
 Excipients that might affect bioavailability are qualitatively and quantitatively 
the same. In general, the use of the same excipients in similar amounts is 
preferred. 
Generally the risks of an inappropriate biowaiver decision should be more critically 
reviewed (e.g. site-specific absorption, risk for transport protein interactions at the 
absorption site, excipient composition and therapeutic risks) for products containing 
BCS class III than for BCS class I drug substances. 
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1.7.6 Determining Drug Product Dissolution Characteristics and Dissolution Profile 
Similarity 
 
1.7.6.1 According to FDA Regulation 
Dissolution testing should be carried out in USP Apparatus I at 100 rpm or Apparatus II at 
50 rpm (or at 75 rpm when appropriately justified) using 500 mL of the following 
dissolution media: (1) 0.1 N HCl or Simulated Gastric Fluid USP without enzymes; (2) a pH 
4.5 buffer; and (3) a pH 6.8 buffer or Simulated Intestinal Fluid USP without enzymes.  
The dissolution testing apparatus used in this evaluation should conform to the 
requirements in USP (Dissolution). Selection of the dissolution testing apparatus (USP 
Apparatus I or II) during drug development should be based on a comparison of in vitro 
dissolution and in vivo Pharmacokinetic data available for the product. The USP Apparatus I 
(basket method) is generally preferred for capsules and products that tend to float, and USP 
Apparatus II (paddle method) is generally preferred for tablets. If the testing conditions need 
to be modified to better reflect rapid in vivo dissolution (e.g., use of a different rotating 
speed), such modifications can be justified by comparing in vitro dissolution with in vivo 
absorption data (e.g., a relative BA study using a simple aqueous solution as the reference 
product).  
A minimum of 12 dosage units of a drug product should be evaluated to support a biowaiver 
request. Samples should be collected at a sufficient number of intervals to characterize the 
dissolution profile of the drug product (e.g., 5, 10, 15, 20, and 30 minutes).  When 
comparing the test and reference products, dissolution profiles should be compared using a 
similarity factor (f2). 
The similarity factor is a logarithmic reciprocal square root transformation of the sum of 
squared error and is a measurement of the similarity in the percent (%) of dissolution 
between the two curves. 
FDA Acceptance Criteria: Two dissolution profiles are considered similar when the f2 
value is ≥50. To allow the use of mean data, the coefficient of variation should not be more 
than 20 percent at the earlier time points (e.g., 10 minutes), and should not be more than 10 
percent at other time points. Note that when both test and reference products dissolve 85 
percent or more of the label amount of the drug in 15 minutes using all three dissolution 
media recommended above, the profile comparison with an f2 test is unnecessary. 
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1.7.6.2 According to WHO Regulation 
Depending on the BCS classification of the API, based on solubility and 
permeability characteristics, the testing procedures are: 
 
A. For pharmaceutical products containing Biopharmaceutics 
Classification System Class I (highly soluble, highly permeable) APIs 
For rapidly dissolving pharmaceutical products containing BCS Class I APIs, 
more than 85% dissolution of the labelled amount is required within 30 
minutes in standard media at pH 1.2, 4.5 and 6.8 using the paddle apparatus at 
75 rpm or the basket apparatus at 100 rpm. The dissolution profiles of the 
comparator and the multisource products should be compared by an similarity 
factor (f2) > 50 or an equivalent statistical criterion. 
If within 15 minutes more than 85% of the API are released from the 
comparator and the multisource formulation under the above-mentioned 
conditions the products will be considered very rapidly dissolving. In this case 
the products are deemed to be equivalent and a profile comparison is not 
required. 
 
B. For pharmaceutical products containing Biopharmaceutics Classification 
System Class III (highly soluble, low permeability) APIs 
A biowaiver can be considered only if both the multisource and the 
comparator product are very rapidly dissolving. Eighty-five percent or more 
dissolution of the labeled amount of the API should be achieved within 15 
minutes in standard media at pH 1.2, 4.5 and 6.8 using the paddle apparatus at 
75 rpm or the basket apparatus at 100 rpm. Generally, the risks of an 
inappropriate biowaiver decision should be more critically reviewed (e.g. site-
specific absorption, induction/competition at the absorption site, excipient 
composition and therapeutic risks) for products containing BCS Class III APIs 
than for BCS Class I drugs. 
 
C. For pharmaceutical products containing APIs with high solubility at pH 
6.8 but not at pH 1.2 or 4.5 and with high permeability (by definition, 
BCS Class II compounds with weak acidic properties) 
These are eligible for a biowaiver provided that the multisource product: 
• is rapidly dissolving, i.e. 85% or more dissolution of the labeled amount of 
the API should be achieved within 30 minutes in standard media at pH 6.8 
using the paddle apparatus at 75 rpm or the basket apparatus at 100 rpm. 
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The multisource product exhibits similar dissolution profiles, as determined 
with the f2 value or equivalent statistical evaluation, to those of the 
comparator product in buffers at all three pH values (pH 1.2, 4.5 and 6.8). 
For multisource products containing BCS Class II API with dose: solubility 
ratios of 250 ml or less, at pH 6.8, the excipients should also be critically 
evaluated in terms of type and amounts of surfactants in the formulation. 
 
1.7.6.3 According to EMA Regulations 
The results of in vitro dissolution tests at three different buffers (Normally pH 1.2, 
4.5 and 6.8) and the media intended for drug product release (QC media), obtained 
with the batches of test and reference products that were used in the bioequivalence 
study should be reported.  
The results should be reported as profiles of percent of labeled amount dissolved 
versus time displaying mean values and summary statistics. Unless otherwise 
justified, the specifications for the in vitro dissolution to be used for quality control 
of the product should be derived from the dissolution profile of the test product batch 
that was found to be bioequivalent to the reference product. 
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1.8 Finished Product Stability Studies  
[Ref (18), (19) (20)] 
Stability is defined as the extent to which the product retains, within specified limits, and 
throughout its period of storage and use (i.e. its shelf-life), the same properties and 
characteristics that it possessed at the time of its manufacture. 
1.8.1 Selection of Batches 
Data from stability studies should be provided on at least three primary batches of the 
pharmaceutical product. The primary batches should be of the same formulation and 
packaged in the same container closure system as proposed for marketing. The 
manufacturing process used for primary batches should simulate that to be applied to 
production batches and should provide product of the same quality and meeting the same 
specification as that intended for marketing. Two of the three batches should be at least pilot 
scale batches and the third one can be smaller, if justified. Where possible, batches of the 
pharmaceutical product should be manufactured by using different batches of the active 
substance. Stability studies should be performed on each individual strength and container 
size of the pharmaceutical product unless bracketing or matrixing is applied. 
 
1.8.2 Climatic Zones 
In order to be able to reduce the amount of stability testing, the number of different long 
term testing conditions must be reduced to a sufficient extent. This has been proposed by 
Paul Schumacher in 1972 and Wolfgang Grimm in 1986 and in 1998 when they defined four 
different long term test conditions, which match with the climatic conditions of the target 
markets categorized in just four different climatic zones (CZ).  
This concept is described in regulatory guidelines and pharmacopoeias and became an 
established standard in developing pharmaceutical products. At the fortieth meeting of the 
WHO Expert Committee on Specifications for Pharmaceutical Preparations, Geneva, 
October 2005, it was recommended to split the current Climatic Zone IV (hot and humid) 
into CZ IVA – for which 30°C/65% RH will remain the standard long term testing condition 
– and CZ IVB, for which, if justified, 30°C/75% RH will become the long term testing 
condition. The following criteria and long term testing conditions are, therefore, proposed: 
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Figure 12: Climatic zone definition according to WHO 
[Ref. (19)] 
 
 
 
 
 
 
Additional testing conditions i.e. accelerated and – if applicable – intermediate conditions 
have to be used as described in this guideline. The detailed analysis of meteorological 
measurements as described above, and the evaluation of the climatic conditions in each 
EMR member state resulted in the following classification and recommended testing 
condition for long term stability studies (Figure 13): 
 
Figure 13: long term testing condition in the Eastern Mediterranean Region according to WHO 
 
* The hottest and most humid climatic zone has been selected to establish the adequate stability testing condition 
for a particular country.  
** Aqueous-based solutions in semi-permeable packaging, and dosage forms sensitive to low humidity, e.g., hard-
gelatin capsules, may require testing at low humidity according to the procedure described in this guideline. 
CZ  Definition 
Criteria 
Mean annual temperature measured in the open air / 
Mean annual partial water vapor pressure 
Long term 
testing 
conditions 
I 
Temperate  
climate 
≤ 15°C / ≤ 11 hPa 21°C / 45% RH 
II 
 
Subtropical and 
Mediterranean 
Climate 
> 15 to 22°C / > 11 to 18 hPa 25°C / 60% RH 
III  
 
Hot and dry  
climate 
> 22°C / ≤ 15 hPa 30°C / 35% RH 
IVA  
 
Hot and humid 
 climate 
> 22°C / > 15 to 27 hPa 30°C / 65% RH 
IVB  
 
Hot and very 
humid climate 
> 22°C / > 27 hPa 30°C / 75% RH 
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1.8.3 Storage Conditions / General Case 
In general, a pharmaceutical product should be evaluated under storage conditions (with 
appropriate tolerances) that test its thermal stability and, if applicable, its sensitivity to 
moisture or potential for solvent loss. The storage conditions and the lengths of studies 
chosen should be sufficient to cover storage, shipment, and subsequent use with due regard 
to the climatic zone(s) in which the product is intended to be marketed.                                               
In addition as part of the development phase, stability studies conducted on one batch of the 
pharmaceutical product for up to three months at 50°C/ambient humidity may be useful to 
identify the formulation and packaging material adequate for extremely hot and dry 
conditions. Photo-stability testing should be conducted on at least one primary batch of the 
pharmaceutical product if appropriate.  
Long-term, accelerated, and, where appropriate, intermediate storage conditions for drug 
products are detailed in Table 4 below.  
 
Table 4 : Recommended Storage condition in the stability study / General Case 
Study Storage condition 
Minimum time period covered by 
data at submission 
Long-term* 
25°C ± 2°C/60% RH ± 5% RH 
30°C ± 2°C/65% RH ± 5% RH 
12 months 
Intermediate** 30°C ± 2°C/65% RH ± 5% RH 6 months 
Accelerated 40°C ± 2°C/75% RH ± 5% RH 6 months 
*  It is up to the applicant to decide whether long-term stability sturdies are performed at 25°C ± 2°C/60% RH ± 5% RH or 
30°C ± 2°C/65% RH ± 5% RH.  
* According to the WHO Eastern Mediterranean Region our region has a long-term study   under 25°C ± 2°C/60% RH ± 5% 
RH 
** If 30°C ± 2°C/65% RH ± 5% RH is the long-term condition, there is no intermediate    condition. 
 
 
1.8.4 Storage Conditions In Palestine 
According to the WHO in eastern Mediterranean region (EMR), the storage conditions in 
Palestine are summarized in table 5: 
Table 5: Stability study storage condition in Palestine 
Study Storage condition 
Minimum time period covered by 
data at submission 
Long-term 25°C ± 2°C/60% RH ± 5% RH 12 months 
Intermediate 30°C ± 2°C/65% RH ± 5% RH 6 months 
Accelerated 40°C ± 2°C/75% RH ± 5% RH 6 months 
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Significant Change and Failure                                                                    [Ref (20)] 
In general, "significant change" for a finished product is defined as:  
1. A 5% change in assay from its initial value; or failure to meet the acceptance criteria for 
potency when using biological or immunological procedures;  
2. Any degradation product exceeding its acceptance criterion;  
3. Failure to meet the acceptance criteria for appearance, physical attributes, and 
functionality test (e.g., colour, phase separation, resuspendibility, caking, hardness, 
dose delivery per actuation); however, some changes in physical attributes (e.g., 
softening of suppositories, melting of creams, partial loss of adhesion for transdermal 
products) may be expected under accelerated conditions. 
 
Additional Stability study: 
[Ref (20)] 
Once the pharmaceutical product has been registered, additional stability studies are 
required whenever major variations are made like the following:  
1.  Change in the manufacturing process;  
2.  Change in the composition of the pharmaceutical product;  
3.  Change of the immediate packaging. 
The stability parameters of drug dosage form can be influenced by environmental conditions 
of storage (temperature, light, air and humidity), as well as primary package components. 
 
1.9 Test method Validation  
[Ref. (21) (22)] 
The quality of drug product starts from formulation of raw material up to evaluation of 
finished product at the end of shelf life, and for valid evaluation the analytical procedure 
must be developed and validated according to the regulations of FDA, USP, etc. 
With refer to Food and drug administration guideline " Analytical Procedures and Methods 
Validation for Drugs and Biologics" several Parameters must be studied and  evaluated 
during method development are specificity, linearity, robustness, ruggedness, range, 
accuracy, and precision. During early stages of method development, the robustness of 
methods should be evaluated because this characteristic can help you decide which method 
you will submit for approval. 
The parameters of test method validation for determination of Pregabalin in product using 
HPLC System are: 
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1.9.1 Linearity and Range: 
Linearity is the ability of the method to elicit test results that are directly proportional to 
analyte concentration within a given range. Linearity is generally reported as the variance of 
the slope of the regression line. Range is the interval between the upper and lower levels of 
analyte concentrations (inclusive) that have been demonstrated to be determined with 
precision, accuracy and linearity using the method as written. The range is normally 
expressed in the same units as the test results obtained by the method. A minimum of five 
concentration levels, along with certain minimum specified ranges are done. For assay, the 
minimum specified range is from 80-120% of the target concentration. For content 
uniformity testing, the minimum range is from 70-130% of the test or target concentration. 
For Related Substances/impurities, linearity demonstrated from 50% of the ICH reporting 
level to 150% of the proposed shelf life specifications of the related substance. For 
dissolution testing, linearity should be demonstrated ±20% over the range of the dissolution 
test (Q-Factor), the minimum range of dissolution test is from Q - 20% to Q + 20%.  
 
1.9.2 Precision: 
Precision is the measure of the degree of repeatability of an analytical method under normal 
operation and is normally expressed as the Relative Standard Deviation (RSD) for a 
statistically significant number of samples. 
Precision is performed at one level, i.e. repeatability. Repeatability is the results of the 
method operating over a short time interval under the same conditions (injection precision or 
instrument precision). It is determined from a minimum of nine determinations covering the 
specified range of the procedure (for example, three levels, three repetitions each), or from a 
minimum of six determinations, at 100% of the test or target concentration.  
1.9.3 Accuracy: 
To verify that Pregabalin in Pregabalin Tablet is close to the true value, the accuracy of an 
analytical procedure measures the closeness of agreement between the value, which is 
accepted either as a conventional true value or an accepted reference value and value found 
(i.e. accuracy is a measure of exactness of an analytical method). 
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It is measured as the percent of analyte recovered by assay, by spiking samples in a blind 
study. Accuracy is evaluated by analyzing synthetic mixtures (Placebo) spiked with known 
quantities of Pregabalin.  
To document accuracy a minimum of nine determinations over a minimum of three 
concentration levels covering the specified range (for example, three concentrations, three 
replicates for each) were collected. It is performed at 80%, 100% and 120% levels of label 
claim. 
At each level studied, replicate samples are evaluated. The RSD of the replicates will 
provide the analysis variation or how the precision of the test method is. The mean of the 
replicates, expressed as % of label claim, indicates how the accuracy of the test method is. 
 
1.9.4 Specificity (Stability Indicating Characteristics): 
To verify that the assay method unequivocally measure accurately and specifically the 
Pregabalin in Pregabalin Tablets in the presence of other components that may be expected 
to be present in the sample matrix. 
It is a measure of the degree of interference from such things as other active ingredients, 
excipients, impurities, and degradation products, ensuring that a peak response is due to a 
single component only. Specificity is measured and documented in a separation by the 
resolution factor between the analyte and neighbor peaks. 
1.9.5 Robustness: 
The robustness of an analytical procedure is a measure of its capacity to remain unaffected 
by small, but deliberate variations in method parameters and provides an indication of its 
reliability during normal usage. 
1.9.6 Ruggedness (Intermediate Precision): 
Ruggedness also known as Intermediate Precision and is the degree of reproducibility of test 
results by the analysis of the same samples under a variety of conditions, such as different 
analysts, instruments or days. 
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1.9.7 Stability of Standard and Sample Solutions (Dissolution Test): 
The stability of the standard and sample solutions verified by preparation of a standard and 
sample solutions and stored under suitable conditions. The standard and sample solutions 
are analyzed over a specified period of time, using a freshly prepared standard and sample 
solutions at each time interval for comparison. The acceptable range for standard/sample 
solution stability is typically between 98% and 102% compared with the initial analysis of 
the standard / sample solutions. 
The procedure may state that the standards and samples need to be analyzed within a time 
period demonstrating acceptable standard and sample solution stability. 
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Part II    Literature Review 
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2.0 Literature review  
2.1 Formulation and Analysis of Pregabalin 
[Re. (23)] 
Noorana Tehseen, Vinay Rao and Mohamad Abdul Hadi had designed twice daily mini-
tablets formulation of Pregabalin under a patent "Design and characterization of a twice 
daily mini-tablets formulation of Pregabalin"; the system comprises of 15 matrix mini-
tablets weighing 25 mg encapsulated in HPMC capsule. For achieving the sustain release 
profile, various viscosity grades of Hydroxypropyl methylcellulose polymer (HPMC K4M, 
K15M, K100M) were used. The mini-tablets were prepared by direct-compression method. 
The compatibility of drug with other ingredients was checked by FTIR studies.  
The values of pre-compression parameters evaluated were within prescribed limits and 
indicated good free flowing property. The in-vitro performance of mini-tablets formulation 
showed the desired behavior; nearly 99.57 % of drug was sustained for a period of 12 hrs. 
FTIR results revealed that there was no interaction between dug and other excipients. The 
stability study revealed that the formulations were found to be stable. 
 
2.2 Test method validation literature review 
[Ref. (24) (25) (26) (27)] 
There is no Compendial test method for the analysis of the Pregabalin tablets for that there 
are many published research for many of the researchers on development and validation the 
Pregabalin test method as: 
 
2.2.1 "Analytical RP-HPLC Method for Development and Validation of Pregabalin 
in Bulk and the Determination of Pregabalin in Tablet Dosage Form" 
In this article "The proposed gradient method was performed using a liquid chromatography 
of model Waters alliance, 2695 separation model. The chromatographic separation was 
achieved on a Waters X-Bridge C18, 3.5µm (150 mm X 4.6 mm) column. The gradient LC 
method employs solution A and B as mobile phase. The solution A contains 0.01 M 
Ammonium acetate in water (pH – 6.8). The solution B contains a mixture of acetonitrile 
and methanol in the ratio of 80: 20. The flow rate was 0.8 ml /min and the detection 
wavelength was 210 nm. For LCMS the above conditions HPLC connected to mass 
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instrument (Micro mass, Quattro micro TMAPI, ESCI Multi mode Ionization, ESI source , 
triple quad analyser ) and detect the mass". [ref. (28)] 
 
Figure 14: Chromatogram of Pregabalin assay test 
 
2.2.2 "Monitoring of Pregabalin in Pharmaceutical Formulations and Human Serum 
Using UV and RP-HPLC Techniques: Application to Dissolution Test Method" 
In this article "Chromatographic separation was performed on a KROMASIL® 100-5 C-18 
column (250×4.6 i.d. mm) (5 µm particle size) as stationary phase with a UV detection at 
210 nm using isocratic elution when buffer pH 7 and acetonitrile (96:4, v/v) were used as 
the mobile phase and the flow rate was 1 ml min-1 at ambient temperature, the retention 
time was 4.6 minutes". (29) 
 
Figure 15: Chromatogram of Pregabalin Dissolution test 
 
2.2.3 Development and Validation of HPLC Method for the Determination of 
Pregabalin in Capsules 
In this article "A simple, precise, specific, and accurate reverse phase HPLC method has 
been developed for the determination of Pregabalin in Tablet dosage form. The 
chromatography was set on Hypersil BDS, C8, 150×4.6 mm, 5 μm column using photodiode 
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array detector. The mobile phase consisting of phosphate buffer pH 6.9 and acetonitrile in 
the ratio of 95:05 with flow rate of 1 ml/min. The method was validated according to ICH 
guidelines with respect to specificity, linearity, accuracy, precision and robustness. Lower 
limit of quantification is 0.6 mg/l. The pregabalin sample solution was found to be stable at 
room temperature for about 26 h". (30) 
 
Figure 16: Chromatogram of Pregabalin Dissolution Test - Literature review 
 
2.2.4 A novel method for the determination of Pregabalin in bulk pharmaceutical 
formulations and human urine samples 
In this article "The proposed method was performed using a liquid chromatography of 
model LC - 2010 CHT (Shimadzu, Kyoto, Japan). Separation was operated on C18 5 µm 
ODS hypersil column (250 mm × 4.6 mm) using methanol - acetonitrile - 0.02 M di – 
potassium hydrogen orthophosphate (K2HPO4) (pH - 7.00) (3: 1: 16, v/v/v) mobile phase at 
a flow rate of 1.0 ml/min. di – potassium hydrogen orthophosphate solution was prepared by 
dissolving 3.5 g K2HPO4 in 1000 ml double distilled water. Final pH of the mobile phase 
was adjusted to 7.00 with 0.01 M orthophosphoric acid, prepared daily and degassed by 
passing through a 0.45 µm Ultipor filter and ultrasonication for 10 min. All separations were 
performed at room temperature with detection at 210 nm". (31) 
 
Figure 17: Chromatogram of Pregabalin Dissolution Test - Literature review 
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Part III   Problems and Objectives 
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3.0 Problems and Objectives 
3.1 The Research Problem 
Pregabalin reference drug product (Lyrica / Pfizer) was developed as opaque hard gelatin 
shell capsules in dosage strengths of 25, 50, 75, 100, 150, 200, 225, and 300mg. To avoid 
any possible patients or pharmacist confusion, the capsules are colored, and imprinted with 
edible ink to indicate the strength and product code, as follows: 
Table 6: Strengths and capsule sizes  of marketed Lyrica capsules. 
Strength [mg] Capsules Size Capsules Color (Body/Cap) 
25 4 White/White 
50 3 White/White(with black ink band) 
75 4 White/Orange 
100 3 Orange/Orange 
150 2 White/White 
200 1 Light Orange / Light Orange 
225 1 White/ Light Orange 
300 0 White/Orange 
The capsules are bulky materials in large capsule sizes, can be susceptible to moisture, 
ingredients can interact with capsules shell, more difficult to fill accurately, and costly, 
while the tablets are well accepted, elegant, may be presented in different sizes and shapes, 
have low manufacturing cost, may be coated, and possible for dose splitting. 
In addition to above, the tablet dosage forms are generally more stable and high capacity of 
manufacturing, different manufacturing approaches and many other advantages. 
The research regarding the development of Pregabalin immediate release tablets is rare, but 
the success in developing stable, reproducible, elegant Pregabalin Tablets, that is Biowaiver 
to reference capsules, will allow pharmaceutical companies that have no designated capsule 
line in the Production Department, to present their product in the market as tablet dosage 
form. 
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3.2 Objectives of the Thesis 
 
Main objectives  
Development, Formulation and evaluation of Immediate release Pregabalin Tablets  
 
Specific Objective  
1. To develop immediate release (IR) Pregabalin tablets with different strengths (75mg 
and 300mg per tablet). 
2. To assess and evaluate the rate and extent of Pregabalin release from the tablets, using 
an appropriate dissolution method. 
3. To develop and validate a suitable quantitative method of analysis for Pregabalin 
Tablet dosage form (dissolution, Assay and related Substances). 
4. To study the stability of Pregabalin Tablets. 
5. To carry out Biowaiver study (dissolution profiles of Pregabalin Tablets versus the 
reference Pregabalin Capsules).    
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Part IV Methodology, Strategy of 
Research and Experiments 
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4.0 Methodology and Strategy of Research 
4.1 Project Outline 
Following are the proposed steps to fulfill the objectives outlined above 
A. Pre-formulation 
 Selection of API and excipients for formulation. 
 Compatibility Study. 
 Formulation Trials. 
 Selection of Formula. 
B. Formulation 
 Implementation of Selected formula. 
 Selection of Packaging Material. 
C. Test Methods Development. 
 Assay and Related test method validation. 
 Dissolution Test method validation 
D. Evaluation of Pregabalin Tablets 
 Finished product evaluation. 
 Biowaiver Study. (Comparison of Dissolution profile of selected formula versus 
Reference Product). 
 Stability Study. 
E. Data Analysis and Discussion. 
F. Report results in thesis format. 
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4.2 Materials and Reagents: 
All material used in the formulation of Pregabalin tablets are of pharmaceutical grade, the 
materials, packaging materials and reagents used are summarized in table (6). 
The following list includes the materials required for formulation, packaging and analysis of 
Pregabalin tablets: 
Table 7: Required Materials and Reagents used in the study 
Purpose No. Item Description Function 
F
o
rm
u
la
ti
o
n
 
1 Pregabalin  
Crystalline powder, 
Pharmaceutical grade 
API 
2 Avicel PH102 
Microcrystalline Cellulose 
Pharmaceutical grade 
Filler/Binder 
3 Avicel PH200 
Microcrystalline Cellulose , 
Pharmaceutical grade 
Filler/Binder 
4 Starch Maize Powder, Pharmaceutical grade 
Disintegrant/
Glidant 
5 Starch (1500) 
Pregelatinized starch Powder, 
Pharmaceutical grade 
Binder/ 
Disintegrant 
6 Magnesium Stearate Powder, Pharmaceutical grade Lubricant 
7 Talc Powder, Pharmaceutical grade 
Glidant / 
Lubricant 
8 Opadry II White Powder, Pharmaceutical grade Coating 
P
a
ck
a
g
in
g
 
1 PVC Brown Roll 250 µm thickness 
Primary 
Packaging 
2 
PVDC/PVC Brown 
Roll 
250 µm/40 µm thickness 
3 Aluminum Foil 20 µm thickness 
A
n
a
ly
ti
ca
l 
1 
Potassium 
dihydrogen 
phosphate. 
Anhydrous powder, analytical 
grade 
Analytical 
Reagent 2 
Potassium 
hydroxide. 
Flakes, analytical grade 
3 Acetonitrile HPLC grade 
4 Water  HPLC grade 
5 Water WFI grade 
Solvent for 
dissolution 
6 Lyrica Capsules 
25mg, 75mg, 150mg, 300mg 
Strengths 
Reference 
Product 
All mentioned material and reagents were donated by Jerusalem pharmaceuticals company, 
Al-Bireh – Ramallah – Palestine. 
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4.3 Tools and Equipment 
Syringes, Vials, pipettes, glassware, stands, tubes and other equipment were supplied by 
Jerusalem Pharmaceuticals Company, all equipment and tools are tabulated in the next table. 
Table 8: Tools and Equipment used in the study of Pregabalin Tablets 
Purpose No. Item Source/Model 
A
n
a
ly
ti
ca
l 
&
 E
v
a
lu
a
ti
o
n
 I
n
st
ru
m
en
t 
1 HPLC Equipped with 
Photodiode Array UV Detector 
Lachrom Elite 
2 UV/VIS spectrophotometer JASCO V-630 
3 FTIR Spectrophotometer Nicolet 
4 Dissolution Tester Electrolab 
5 Bulk/Tap density meter NA 
6 Hardness Tester HM LHT-2 
7 Friability Tester Vankel 
8 Moisture Analyzer Sartorius 
9 Digital Caliber TESA Sr. 6N 1948 
10 Analytical balances Radwag 
11 Magnetic Bars Freed electric 
12 Hotplate with stirrer Freed electric 
13 Computer HP 
14 Funnels, different sizes Glass A grade 
15 PH Meter Metrohm 691 pH Meter 
16 Nylon Membrane 0.45 microns Mercck Millipore Millex-HN 
17 Refrigerator Kirsch Co. 
18 Sonicator Elmasonic S450 
19 Water bath Local manufacturer 
20 Spatulas Stainless Steel Spatula 
21 Vortex VLEP Scientifica 
22 Octadecylsilane chemically 
bonded to totally porous silica 
particles (4.6mm * 25cm) HPLC 
Column 
Luna HPLC Column 
23 Three Climatic Chambers: 
(1) 25±2 C/60±5% RH 
(2)  30±2 C/65±5%RH 
(3) 40±2 C/75±5%RH 
 
Firlabo 
PGC-USA 
Firlabo 
P
ro
d
u
ct
io
n
 
E
q
u
ip
m
en
t 
24 Sifter & Meshes (Mesh#20, 
Mesh#30, Mesh#60, Mesh#120) 
Sieve Master 
25 Tablet Compression Machine. HM Pharmachine 
26 10 mmx 5mm oblong  punches, 
19mm x 9 mm oblong  punches 
Pearl Elizabeth 
27 Coating System Local manufacturer 
28 Blistering Machine  
T
o
o
ls
 
29 Beakers 100ml, 300ml, 1000 ml Glass grade B 
31 Volumetric Pipettes Glass grade A 
32 Graduated Cylinder (1000ml) Glass grade B 
33 
Volumetric Flasks (50, 100; 
200;1000 ml) 
Glass grade A 
34 Erlenmeyer flasks Glass grade B 
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4.4 Pre-Formulation 
4.4.1 Selection of API and excipients  
Pregabalin is not found in any international pharmacopeia, it is a white to off-white, highly 
crystalline, non-hygroscopic powder. 
Pregabalin used in this study is synthesized as the single enantiomer S, and has consistent 
polymorph Form I. (Ref. Patent US 2006/0270871 AI)  
Particle Size is part of the specification of API, but is not expected to be critical parameter 
with regards to the bioavailability of the drug product, taking into the account the water 
solubility of Pregabalin. 
According to "HandBook of Pharmaceutical Excipient 4
th
 edition" there is a relation 
between the type, function and concentration of excipients. 
The Specifications and COA of Pregabalin used are shown in Appendix 1. 
All excipients used are of pharmaceutical grade and used in percentages according to FDA 
as illustrated in Table 8. They are tested and evaluated before use, and the COAs are shown 
in Appendix 1. 
Table 9: List of some Excipients and their application 
Excipient Application % Concentration 
MCC PH102 "Avicel" Adsorbant 20-90 
Anti-adherant 5-20 
Tablet disintegration 5-15 
Tablet binder/ diluent 20-90 
Capsule binder/ diluent 20-90 
Starch 1500 Tablet binder  
(direct compression) 
5-20 
Tablet disintegrant 5-10 
Starch Maize Tablet Glidant 3-10% 
Disintegrant 3-25 
Talc Glidant / lubricant for tablet 1- 10 
Magnesium Stearate Lubricant in Tablet and 
capsule 
0.25-5 
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4.4.2 Compatibility Study: 
                                                                                                                                 [Ref (32) (33) (34) (35) (36)] 
The purpose of this stage is to find compatible excipients with the active ingredient 
Pregabalin. The study is done by obtaining the FTIR spectra for each excipient alone and for 
its mixture with Pregabalin, then analyzed for any possible drug- excipient interactions. 
 
Figure 18: Pregabalin Structure 
 
Sample preparation 
The physical mixtures were prepared in 1:1 ratio for each excipient with Pregabalin and then 
passed through intended mesh as manufacturing procedure. Samples of Pregabalin and 
excipients were placed in glass vial type 1, closed and labeled. Then the vials were stored 
under stressed conditions at 40˚C for 30 days. The compatibility of drug with excipients was 
studied by FT-IR. 
The Physical mixture were prepared according to Table 10 
Table 10: Samples preparation for compatibility study 
API Excipient Ratio  
[API: Excipient] 
Mesh# for 
Excipient * 
Pregabalin MCC PH102 1:1 60 
Pregabalin Talc 1:1 60 
Pregabalin Magnesium Stearate 1:1 100 
Pregabalin Starch Maize 1:1 60 
* Pregabalin was sieved through mesh No. 35 
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4.5 Selection the formula 
All excipients used are widely involvement in oral pharmaceutical dosage without any toxic 
or irritant problem or excipient-excipient physically or chemically interaction. 
The reference Pregabalin drug product (Lyrica capsules) contains lactose monohydrate, 
maize starch and talc as excipients in addition to the API Pregabalin. In the design of 
Pregabalin Tablet we used Microcrystalline cellulose in two different grades as binder/ 
diluent, talc powder as Glidant, Magnesium stearate as lubricant and Starch/Pregeltinized 
starch used as Glidant-disintegrant 
The planned series of formulae are listed in Table 11. 
Table 11: Formulae of Pregabalin Tablets 
Function Ingredient 
Quantity * (mg) 
F-1 F-2 F-3 F-4 F-5 F-6 F-7 
API Pregabalin API 
300×2 
(91.7%) 
300 
(52.1%) 
300 
(52.1%) 
300 
(49.5%) 
300 
(45.7%) 
300 
(45.3%) 
300 
(45.3%) 
Filler/ Binder 
MCC - Avicel pH102 
--- 
 
200 
(34.7%) 
--- 
 
200 
(33.0%) 
300 
(45.7%) 
--- 
 
300 
(45.3%) 
MCC - Avicel 200 
--- 
 
--- 
 
200 
(34.7%) 
--- 
 
--- 
 
300 
45.3%) 
--- 
 
Disintegrant 
Starch Maize 
--- 
 
40 
(6.9%) 
40 
(6.9%) 
70 
(11.6%) 
--- 
 
--- 
 
20 
(3.0%) 
Pregelatinized starch 
1500 
--- 
 
--- 
 
--- 
 
--- 
 
20 
(3.0%) 
20 
(3.0%) 
--- 
 
Lubricant Magnesium Stearate 
27×2 
(8.3%) 
6 
(1.0%) 
6 
(1.0%) 
6 
(1.0%) 
6 
(0.9%) 
12 
(1.8%) 
12 
(1.8%) 
Glidants Talc 
--- 
 
30 
(5.2%) 
30 
(5.2%) 
30 
(5.0%) 
30 
(4.6%) 
30 
(4.5%) 
30 
(4.5%) 
Weight of Tablet* 654 576 576 606 656 662 662 
* Quantities are calculated for one unit. 
* Batch Size is 1000 tablet for each Trial formula. 
 
The powder blends were tested before compression for their flowability, and the compressed 
tablets were tested for their mechanical properties (hardness, friability, average weight, 
weight uniformity, thickness, and disintegration time and tablet appearance). 
The analytical methods are specified in the following sections of this chapter, and the results 
are summarized in Chapter 5, The Flowability of powder blends can be described according 
to Table 12. 
 Formula selection will depend on ease of production, flowability of powder blend and 
performance of compressed tablets. 
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Table 12: Carr Index Classification and Powder Flowability 
Carr Index (%) Flow 
 
Hausner ratio 
5 – 12  Free flowing The Hausner ratio varies from about 1.2 
for a free - flowing powder to 1.6 for 
cohesive powders.  
 
12 – 16 Good 
18 – 21  Fair to passable* 
23 – 35  Poor* 
33 – 38  Very poor 
≥40  Extremely poor 
Calculation method 
Carr index (compressibility) = 
 
          (Tapped density- Untapped density) 
-----------------------------------------------     x 100                 
Tapped density 
                              Tapped bulk density 
Hausner ratio = ----------------------------- 
                            Poured bulk density 
 
* May be improved by the addition of glidant. 
 
All results are recorded, tabulated and discussed in Chapter 5. 
4.6 Manufacturing Procedure 
The general manufacturing procedure of tablet formulations shown in table 11 is: 
1.0 All components are accurately weighted according to the intended formula. 
2.0 All components are passed manually through the corresponding US Sieve No. 
Pregabalin: Sieve No.35 
Magnesium Stearate: Sieve No.100 
All other components: Sieve No. 60 
3.0 All components except lubricant and glidant are combined and mixed together 
manually in standard size of PE bag for about 10 minutes. 
4.0 Lubricant and glidant are added to blend and mixed for 30 seconds. 
5.0 Blends are compressed using pilot rotary tablet press, equipped with eight oblong 
punches 
6.0 In-process control of weight variation is carried out during compression at least twice. 
Weight values reported in milligram. Mean and SD are calculated at weight variation 
±5%. In addition to weight, compression difficulties e.g. sticking, capping and tablet 
appearance are noted. 
7.0 Repeat the previous prescribed method of tablet manufacturing, and compressed about 1000 
tablets from each tablet formulation. 
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4.7 Implementation of Selected Formula 
Pregabalin tablets, with two strengths 300mg tablet and 75mg tablet were prepared and 
coated using the component ratio of selected formula, and the mentioned general 
manufacturing process  
The composition of two strengths are dose weight proportional i.e. the percentage of each 
excipient relative to the API is the same or not exceeding Level 1 change, as illustrated in 
table 13. 
Table 13: Selected formula F5 and the Size of Batch for further study 
Ingredient 
Pregabalin Tablet 300mg Pregabalin Tablet 75mg 
Quantity / Unit 
(mg) 
Relative 
to API 
 
Relative to 
weight of 
core tablet 
Quantity / 
Unit (mg) 
Relative 
to API 
 
Relative to 
weight of 
core tablet 
Pregabalin API 300.0  100% 45.7% 75.0 100% 45.7% 
Avicel PH 102 300.0 100% 45.7% 75.0 mg 100% 45.7% 
Pregelatinized starch 1500 20.0 6.6% 3.1% 5.0 mg 6.6% 3.1% 
Magnesium Stearate 6.0 2.0% 0.9% 1.5 mg 2.0% 0.9% 
Talc 30.0 10.0% 4.6% 7.5 mg 10.0% 4.6% 
Weight of core Tablet 656 - - 164 -- - 
Opadry II white 14 2.1%* -- 3.5 mg 2.1%* -- 
Water purified** 86 -- -- 21.5 mg -- -- 
Weight of coated Tablet 670.0 mg   167.5 mg   
Batch Size 2000 Tab 8000 Tab 
*Relative to weight of core tablet 
**Evaporated during drying in coating stage 
  
The prepared tablet cores were coated, by using ready mixed coating powder (Opadry II 
white). The coating process was carried out in conventional coating pan rotated at 18rpm, 
inlet air temperature was 45-50C, and spraying rate was 10 ml/min 
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The Pregabalin tablets manufacturing procedure is summarized in the next flowchart:  
Weighing of All 
Compomenet
Receiving & Input check 
Sieving in Sieve Master 
(Mesh# 30, 60 & 120)
Pregabalin API
Filler/Binder – MCC 
pH102
Disintegrant (Starch 
1500)
Prepare production order 
according to the selected 
Formulation
Pre-Mixing
Final Mixing
Compression Process
Coating Process
Packaging
Blistering
Lubricant (Magensium 
Stearate)
Glidant (Talc)
Visually Test
Uniform content
 Flowability
Uniform powder
Visula Test
Uniformity Content
 Flowability
 Powder color
Assay
Color & Odor
 Shape
Diameter
 Thickness
Appearance of Coat
Weight / Tablet
Uniformity of weight
Uniformity of dosage 
units
 Identification
Hardness
 Friability
Disintegration time
Dissolution
Related Substances
Assay
 Sealing Temperature
 Sealing Pressure.
 Speed of Sealing
Input Material Process Evaluation Test 
Coating Solution
(Opadry II white -
HPMC)
Color & Odor 
 Shape
Diameter
Average weight
Uniformity of Dosage 
Unit “
Weight Variation
 ”Friability
Hardness Thickness
Disintegration
Dissolution
Assay
All Component
 
Figure 19: Process flow chart for manufacturing Pregabalin tablet by direct compression 
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4.8 Test Methods 
4.8.1 Pregabalin blends Characterization 
Hausner ratio is calculated for each formulation as follows:  
Weigh an empty 100-ml glass cylinder (W0). Pass the powder through sieve mesh # 16, and 
fill sufficient quantity of powder to an apparent volume of about 70 ml, and reweigh (W1). 
Record the volume of powder as (V0). The cylinder is allowed to jolt for 1000 taps using 
Erweka SVM Tapped density Tester, and the tapped volume is recorded (V1). The bulk, 
tapped densities and Hausner ratio are calculated as follows: 
             
     
  
 
               
     
  
 
                
              
            
 
 
Evaluation criteria: Values of Hausner Ratio less than 1.25 indicate good flow, while 
values higher than 1.5 indicate poor powder flow. 
4.8.2 General Appearance 
The general appearance (color, shape, thickness and surface) of the formulated tablets was 
inspected and tested visually, while the dimensions were measured by using a suitable 
caliper. 
Thickness: The thickness of the tablets was determined using a thickness TESA dial caliper 
150mm/6 in. Ten tablets from each batch are used.  
Thickness values are reported in millimeters. Mean and SD are calculated. 
 
4.8.3 Hardness 
Tablet hardness or breaking force is measured by placing the tablet between two platens of 
the hardness tester, one of which moves to apply sufficient force to the tablet to cause 
fracture. The force required to cause fracture is recorded. It is repeated for 10 tablets and the 
hardness values are reported in kilograms force (Kgf). Mean and SD are calculated. 
Acceptance Criteria: NLT 5 Kgf 
 
4.8.4 Friability 
Friability is carried out as per USP 38 <1216>: For Pregabalin 75mg tablets, take a sample 
of whole tablets corresponding as near as possible to 6.5 g. For Pregabalin 300mg tablets, 
take a sample of 10 whole tablets. The tablets is carefully dedusted prior to testing.. 
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Accurately weigh the tablet sample, and place the tablets in the drum of friabilator (Copley 
FR1000 Friabilator). Rotate the drum 100 times, and remove the tablets. Remove any loose 
dust from the tablets as before, and accurately weigh. 
Acceptance Criteria: maximum mean weight loss from the three samples of not more than 
1.0% is considered acceptable for most products. 
 
4.8.5 Assay and related tests 
Assay and related substances test method are described under “Test Methods Validation 
(Methodology)” section. 
Acceptance limit: 90.0%-110.0% 
 
4.8.6 The Uniformity of dosage Units: 
The uniformity of dosage units in Pregabalin Tablets can be demonstrated by Weight 
Variation and that depend on the weight of active ingredient (≥25mg) and the percent of 
label claim (≥25%). 
Uniformity of dosage units test as per USP Method <905> is carried out by means of weight 
variation. i.e. 10 tablets of each formulation are accurately weighed individually using an 
electronic balance (Precisa XT 2208). The Pregabalin content of each unit is calculated 
expressed as percent of label claim from the weight of the individual tablet and the result of 
the assay. Acceptance value (AV) is calculated according to USP chapter <905>. 
 
Acceptance value: AV should not be more than 15.0. Each tablet should contain between 
85.0% and 115.0% of label claim. 
 
4.8.7 Disintegration Test 
Carry out the test in Purified water using USP Disintegration tester. Record the time when 
the tablet disintegrate and all particles pass through  mesh # 10 screen. If any residue 
remains, it must have a soft mass.  
Acceptance Criteria: Disintegration time not more than 15min. 
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4.8.8 Dissolution Testing: 
[Ref (13), (37)] 
The dissolution rate studies are carried out by using dissolution tester apparatus USP Type II 
(paddle type).  
Sample size (n): 6 tablets. 
Detection UV Wavelength: 280nm 
Table 14:  Dissolution Parameters 
 
 
 
 
 
 
 
 
The dissolution test is performed as per method detailed in section “Validation of Test 
Methods”.  
The dissolution rates of tablets are monitored using Erweka EDT. Six Tablets are tested. The 
amount dissolved of Pregabalin is determined by Lachrom HPLC System at wavelength 280 
nm.   
Filtered sample solution is compared to standard solution of known concentration of 
Pregabalin WS. The percent drug dissolved at each sampling time is calculated after 
correction for the cumulative amount removed in previous samples. 
Acceptance Criteria:  Not Less than 75.0 % (Q) of the labeled amount of Pregabalin is 
dissolved within 30 minutes 
 
 
 
 
Parameters Types and Value 
Dissolution apparatus  USP Apparatus II (paddle) 
Dissolution medium  0.06 N HCl solution 
Temperature  37 ±0.5°C 
Initial volume  900 ml 
Speed  50 rpm 
Filter size  0.45μm 
Volume withdrawn  5 ml 
Volume replaced  5 ml 
Sampling times: 10, 15,  30, 45 minutes 
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4.9 Biowaiver Study 
[Ref. (38)] 
The comparison dissolution study is performed between the reference drug product (Lyrica 300mg and 
75mg Capsules) and Samples from Pregabalin 300mg and 75mg Tablets processed by the selected 
formulation. Sample size for each run is six tablets. 
Table 15: In-Vitro comparison dissolution parameters 
Parameters Types and Value 
Dissolution apparatus  USP Apparatus II (paddle) 
Dissolution medium  1. 0.06N HCl solution 
2. Acetate buffer pH 4.5 
3. Phosphate buffer pH 6.8 
Temperature  37 ±0.5°C 
Initial volume  900 ml 
Speed  50 rpm 
Filter pore size  0.45μm 
Volume withdrawn  5 ml 
Volume replaced  5 ml 
Sampling times: 10, 15, 30, 45 minutes 
Detection UV Wavelength 280nm 
 
Similarity factor Calculation 
The similarity factor (f2) given by SUPAC guidelines for Immediate release dosage form 
was used as a basis to compare dissolution profile. The dissolution profiles of products are 
compared using a similarity factor (f2). This similarity factor is calculated by following 
formula: 
          
[
 
 
 
   
√  
∑ [ ̅( )   ̅( )]        
 ]
 
 
 
 
R(t) = mean % API dissolved of reference product at time point x 
T(t) = mean % API dissolved of test product at time point x  
 
Two dissolution profiles are considered similar when the f2 value is ≥50.  To allow the use 
of mean data, the coefficient of variation should not be more than 20% at the earlier time 
points (e.g., 10 minutes), and should not be more than 10% at other time points. 
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4.10  Finished Product Stability Studies  
[Ref (18), (19)]: (19)] 
The stability of the finished product is carried out in its final marketed package, in 
compliance with storage conditions illustrated below 
Stability Study is evidence of how the quality of an Active Pharmaceutical Ingredient (API) 
or Finished Pharmaceutical Product (FPP) varies with time under the influence of a variety 
of environmental factors such as temperature, humidity and light. 
Environmental Conditions 
Samples from the selected formula will be kept at different environmental conditions as 
given below for a month and will be analyzed at initial, 14 days and 30 days. 
Table 16: Stability Environmental Conditions 
Study Storage Condition Testing time interval 
Long Term 
25
o
C ± 2
o
C/ 
60% RH± 5% RH 
initial, 14 days and 30 days 
Intermediate 
30
o
C ± 2
o
C/  
65% RH± 5% RH 
initial, 14 days and 30 days 
Accelerated 
40
o
C ± 2
o
C/ 
75RH± 5% RH 
initial, 14 days and 30 days 
1.  
Stability parameters 
The tablets Stability will be evaluated for the following parameters: Physical appearance, 
Dissolution rate, Disintegration time, Hardness, Friability, Drug content assay and Degradation. 
 
4.11 Test Methods Validation (Methodology) 
4.11.1 Assay and Related substances  
 
Preparations and HPLC Conditions 
 
Buffer Preparation 
Accurately weigh and transfer about 1.36 g Potassium Dihydrogen phosphate in 1000ml of 
water, sonicate to dissolve .Adjust the pH of the Solution to 6.9 ± 0.1 with Potassium 
hydroxide. Filter using a 0.45 µm membrane filter. 
 
Mobile Phase:  
Prepare a filtered and degassed mixture of Buffer, and acetonitrile (94:6). 
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Stock Standard Solution (10.0 mg/ml): 
Transfer an accurately weighed 2000 mg of Pregabalin to a 200-ml volumetric flask, 
dissolve and dilute with Mobile Phase to volume; and mix, Filter through 0.2m membrane 
filter. 
 
 
Nominal Standard Solution (1.0 mg/ml): 
Transfer an accurately measured 5-ml of stock standard solution to a 50-ml volumetric flask 
and dilute with Mobile Phase to volume, and mix, to obtain a solution having a known 
concentration (1.0 mg/ml of Pregabalin). 
 
 
System Suitability Solution (5.0 mg/ml): 
Transfer an accurately weighed 250 mg of Pregabalin and 5.0 mg of RS Impurity IV 
(Lactam) to a 50-ml volumetric flask, Add about 20-ml o Mobile phase, sonicate for about 
15 minutes, dilute with Mobile Phase to volume; and mix, Filter through 0.2m membrane 
filter. 
 
 
Chromatographic Conditions:  
Detection Wavelength: 210 nm.  
Column: Octadecylsilane chemically bonded to totally porous silica particles, 5 to 10µm in 
diameter (25cm X 4.6 mm id). 
Flow Rate: 1.5 ml/min.  
Column Temperature: Ambient Temperature.  
Injection Volume: 20 µL.  
 
 
Procedure: 
General points to consider: 
1. The stock standard and sample solutions are dissolved and diluted to final volume with 
Mobile Phase. 
2. The test and standard concentrations are close if not the same. 
3. The test samples are bracketed by standards during the analytical procedure. 
4. Test samples are filtered before injection or before further dilution. 
 
 
The criteria of test method validation for assay determination of Pregabalin in Pregabalin 
Tablets using HPLC System are: 
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4.11.1.1 Linearity and Range: 
Preparation of Standards: Using the Stock Standard Solution (10.0 mg/ml of Pregabalin) to 
prepare separate standards covering the range between (40%-160%) of the nominal 
concentration according to the following table: 
Table 17: preparation of linearity solution 
Conc. 
(%) 
Conc. of Pregabalin 
(mg/ml) 
Volume Pipetted 
from Stock St 
Solution (ml) 
Volumetric 
Flask Final 
Volume (ml) 
40 0.4 2 50 
60 0.6 3 50 
80 0.8 4 50 
100 1.0 5 50 
120 1.2 3 25 
140 1.4 7 50 
160 1.6 4 25 
 
 
Data Analysis:   
Plot Intensity versus standard concentrations prepared for linearity over the range of 
standard solutions and calculate: 
 The least squares linear regression analysis of the linearity data. 
 The RSD for replicates of each concentration over the range. 
 Determine slope and Y-intercept. 
Acceptance Criteria:  
The correlation coefficient (R
2
) is not less than 0.990 for the least squares method of 
analysis of the line. The RSD of the standards will not be greater than 5.0% at all standard 
concentrations. 
4.11.1.2 Intermediate Precision (Ruggedness): 
Procedure: 
This test is performed by analysis of the nominal standard solution (1.0 mg/ml of 
Pregabalin) by different analyst and on different days (matrix design). Inject the working 
standard solution at nominal concentration (1.0 mg/ml of Pregabalin) into the liquid 
chromatograph six times. 
Calculate the relative standard deviations (RSD) of the replicate injections. 
Acceptance Criteria: Verify that, the Relative Standard Deviation for the replicate 
injections is not more than 2.0% 
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4.11.1.3 Precision: 
Inject the nominal standard solution six times into the liquid chromatograph. 
Calculate the RSD of the replicate injections for the nominal standard concentration (100% 
Concentration, 1.0 mg/ml Pregabalin) and verify that the RSD is not greater than 2.0% 
 
4.11.1.4 Accuracy: 
Procedure:  
Pregabalin Tablets Placebo Preparation: 
Prepare Pregabalin Tablets placebo according to the formulation procedure of Pregabalin 
Tablets. The concentration of placebo in the analyzed sample (Nominal Concentration 1.0 
mg/ml of Pregabalin) is expected to be about 1.0 mg/ml.   
Stock Placebo Preparation (10.0 mg/ml): 
Transfer an accurately measured 1000mg of Pregabalin Tablets Placebo to a   100-ml 
Volumetric Flask. Dissolve and dilute with Mobile Phase to volume, mix and Filter through 
0.2µm membrane filter, to obtain a solution having a concentration (10.0mg/ml of Placebo). 
Preparation of Spiked Samples: 
Place the required placebo volume into the analysis flask and add known amount of 
Pregabalin by volume from the stock standard solution to the analysis flask according to the 
following table: 
Table 18: Preparation Solution of Accuracy test 
Conc. 
(%) 
Placebo 
Conc. 
(mg/ml) 
Pregabalin 
Conc.                 
(mg/ml) 
Pipetted Volume of 
Stock Placebo 
(2)
 
Pipetted Volume 
of Stock St. 
(1)
 
Flask 
Volume 
(ml) 
(3)
 
80 0.8 0.8 4-ml 4-ml 50 
100 1.0 1.0 5-ml 5-ml 50 
120 1.2 1.2 3-ml 3-ml 25 
1: Stock Standard Solution. 
2: Stock Placebo Solution. 
3: Volumetric flask (ml) diluted to final volume with Mobile Phase (as sample preparation in the Pregabalin TM) 
 Analyze the prepared Solutions according to the test method of analysis for Pregabalin 
Tablets. 
 Calculate the recovery data for each determination; calculate the average of recovery 
data and the RSD for each level. 
 Verify that the mean recovery of the assay should be within 100±2.0% at each 
concentration over the range of 80% – 120% of the nominal concentration. 
 
Acceptance Criteria: The mean recovery of the assay should be within 100±2.0% at each 
concentration over the range of 80% – 120% of nominal concentration. 
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4.11.1.5 Specificity (Stability Indicating Characteristics): 
Procedure: 
Different reagents were added to the Nominal Standard Solution (1.0 mg/ml of Pregabalin) 
and added to the Pregabalin Tablets samples (placebo spiked in Pregabalin standard). 
Stressed standard and sample solutions prepared according to the following table: 
 
Table 19: Stress condition and solution preparation – Specificity Test 
Tablets 
No. 
Pipetted Volume 
from Stock St.
(1)
 
Pipetted Volume 
from Stock Placebo
(2)
 
Reagent Added/ 
Stress Condition 
Total Volume 
(ml)
3
 
1 5-ml 5-ml --- 50 
2 5-ml 5-ml 0.5M HCl 50 
3 5-ml 5-ml 0.5M NaOH 50 
4 5-ml 5-ml 6% H2O2 & Heat at 
70
o
Cfor 15 min. 
50 
5 5-ml 5-ml 
Heat in water bath 
at 70
o
C for 1-Hour 
50 
1: Stock standard solution prepared in section 5.3 (10.0 mg/ml of Pregabalin). 
2: Stock Placebo Solution was prepared in section 6.3.3.3 (5.674 mg/ml of Pregabalin placebo). 
3: Volumetric flask (ml) diluted to final volume with Mobile Phase solution. 
Verify the Pregabalin peaks will have baseline of chromatographic resolution of at least 1.5 
from all other sample compounds, or the unresolved components at their maximum expected 
levels. 
 
 
4.11.1.6 Robustness: 
Procedure: 
Use the nominal standard solution (1.0 mg/ml Pregabalin). 
Variation of Method Parameters:  
 Flow Rate: Variation of the flow rate to 1.65 ml/min instead of 1.50 ml/min. 
 Detection Wavelength: Variation of wavelength to 208nm instead of 210 nm. 
Inject the nominal standard solution (1.0 mg/ml of Pregabalin) into the Liquid 
Chromatograph six times and analyze according to Pregabalin Tablets test method. 
Data Analysis: 
Verify that the influence of variation in method parameters is within the previously 
acceptance criteria, the parameter said to be within the methods robustness range. 
Acceptance Criteria: Verify that, the Relative Standard Deviation for the replicate 
injections is not more than 2.0%. 
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4.11.2 Validation Methodology for Dissolution 
Preparations and Chromatographic HPLC Conditions: 
Phosphate buffer: Accurately weigh and transfer about 1.36 g Potassium dihydrogen 
phosphate in 1000ml of water, sonicate to dissolve. Adjust the pH of the Solution to 6.9 ± 
0.1 with Potassium hydroxide. Filter using a 0.45 µm membrane filter. 
Mobile Phase: Prepare a filtered and degassed mixture of Buffer, and acetonitrile (94:6). 
 
Stock Standard Solution (3.333 mg/ml): 
Transfer an accurately weighed 666.6mg of Pregabalin WS to a 200-ml volumetric flask. 
Dissolve and dilute with dissolution medium (distilled water) to volume, and mix, Filter 
through 0.2m membrane filter, to obtain a solution having a known concentration of 
Pregabalin WS (3.333 mg/ml). 
Nominal Standard Solution (0.3333 mg/ml): 
Transfer an accurately measured 5-ml of stock standard solution to a 50-ml volumetric flask 
and dilute with dissolution medium to volume, and mix, to obtain a solution having a known 
concentration (0.3333 mg/ml of Pregabalin WS). 
Chromatographic HPLC Conditions:  
Detection Wavelength: 210 nm. 
Column: Octadecylsilane chemically bonded to totally porous silica particles (4.6mm * 
25cm). 
Flowrate: 1.5 ml/min 
Temperature: Ambient Temperature. 
 
Dissolution Test Conditions: 
Dissolution Medium: 0.06N HCl Solution. 
Apparatus: 6 (Paddle). 
R.P.M: 50 
Time: 30 min. 
Volume: 900 ml. 
 
 
 Procedure: 
General points to consider: 
5. The stock standard and sample solutions are dissolved and diluted to volume with 
dissolution medium. 
6. The test and standard concentrations are close if not the same. 
7. The test samples are bracketed by standards during the analytical procedure. 
8. Test samples are filtered before measured or before further dilution. 
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The criteria of test method validation for Dissolution determination of Pregabalin in 
Pregabalin Tablets using Chromatographic HPLC are: 
4.11.2.1 Linearity and Range: 
Procedure: 
Preparation of Standards: Using the Stock Standard Solution (3.333 mg/ml of Pregabalin 
WS) to prepare separate standards covering the range between (40%-150%) of the nominal 
concentration according to the following table: 
Table 20: Solutions for Linearity Test 
Conc. (%) 
Conc. of Pregabalin 
WS (mg/ml) 
Volume Pipetted 
from Stock St 
Solution (ml) 
Volumetric Flask 
Final Volume (ml) 
40 0.1333 2 50 
60 0.1999 3 50 
80 0.2666 4 50 
100 0.3333 5 50 
120 0.3999 3 25 
150 0.4999 3 20 
 
Data Analysis:   
Plot Intensity versus standard concentrations prepared for linearity over the range of 
standard solutions and calculates: 
 The least squares linear regression analysis of the linearity data. 
 The RSD for replicates of each concentration over the range. 
 Determine slope and Y-intercept. 
 
Acceptance Criteria: The correlation coefficient (R
2
) is not less than 0.98 for the least 
squares method of analysis of the line. Also, the RSD of the standards will not be greater 
than 5.0% at all standard concentrations. 
 
4.11.2.2 Precision: 
Inject the nominal standard solution six times into the liquid chromatograph. 
Calculate the RSD for the replicate readings of the nominal standard concentration (100% 
Concentration, 0.3333 mg/ml Pregabalin WS) and verify that the RSD is not greater than 
5.0%. 
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4.11.2.3 Accuracy: 
It is measured as the percent of analyte recovered by assay, by spiking samples in a blind 
study. Accuracy is evaluated by analyzing synthetic mixtures (Placebo) spiked with known 
quantities of Pregabalin WS. 
To document accuracy a minimum of nine determinations over a minimum of three 
concentration levels covering the specified range (for example, three concentrations, three 
replicates for each) were collected. It is performed at 50, 75 and 100% levels of label claim. 
At each level studied, replicate samples are evaluated. The RSD of the replicates will 
provide the analysis variation or how the precision of the test method is. The mean of the 
replicates, expressed as % of label claim, indicates how the accuracy of the test method is. 
Procedure: 
Pregabalin Tablets Placebo Preparation: 
Prepare Pregabalin Tablets placebo according to the formulation procedure reported in the 
production file of Pregabalin 300mg Tablets. The concentration of placebo in the analyzed 
sample (Nominal Concentration 0.333 mg/ml of Pregabalin WS) was estimated according to 
the final formula. 
Preparation of Spiked Dissolution Samples: 
Place the required placebo weight into the dissolution vessels and add known amount of 
Pregabalin WS by volume from the stock standard solution to the dissolution vessels 
according to the following table: 
Table 21: Sample preparation for accuracy test 
Spiked Sample Preparation 
Conc. 
(%) 
Placebo wt. 
(mg) 
Pregabalin weight 
(mg) 
Pregabalin WS Vessel 
Conc. (mg/ml)             
Diluent Volume 
50 150.0 150.0 0.1666 900 
75 225.0 225.0 0.2500 900 
100 300.0 300.0 0.3333 900 
Standard Preparation 
Conc. (%) Conc. of Pregabalin 
WS (mg/ml) 
Volume Pipetted from 
Stock St Solution (ml) 
Volumetric Flask 
Vol. (ml) 
50 0.1666 1 20 
75 0.2500 15 200 
100 0.3333 5 50 
 *: Note: Dilute to volume of the Volumetric flask with dissolution medium. 
**: Use Stock Standard Solution (3.333 mg/ml). 
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 Analysis of Spiked Samples 
 After completion of Dissolution Test (after 30 minutes) filter a portion of dissolution 
solution from each vessel and take 10 ml of the filtrate to 25 ml with the dissolution 
medium and mix, then analyze collected samples according to the test method of analysis 
for Pregabalin Tablets. 
 Calculate the recovery data for each determination; calculate the average of recovery data 
and the RSD for each level. 
 Verify that the mean recovery of the assay should be within 100±5.0% at each 
concentration over the range of 50–100% of the nominal concentration. 
 
4.11.2.4 Robustness / Dissolution Tester Conditions Variation: 
Preparation of Spiked Dissolution Samples: 
Transfer an accurately weighed 300mg of Pregabalin to the dissolution vessel and add 
weighed quantity (300mg) of Pregabalin Tablets placebo, complete to volume by add 900-
ml of dissolution medium to the vessel. 
Variation of Test Method Parameters:  
 Detection Wavelength: Variation of Detection wavelength to 212 nm instead of 210 nm. 
 Flow rate: Variation of Flow rate to 1.6 ml/min instead of 1.5 ml/min. 
Variation of Dissolution Parameters:  
 R.P.M: Variation of the RPM to 48rpm instead of 50rpm. 
After completion of the dissolution test filter a portion of solution from each vessel and 
analyze according to the test method of analysis for dissolution determination of 
dissolved Pregabalin WS in Pregabalin Tablets. 
 Print out the results. 
 
Data Analysis & Acceptance Criteria: 
Verify that the influence of variation in method parameters and dissolution conditions are 
within the previously acceptance criteria, the parameter said to be within the methods 
robustness range. 
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4.11.2.5 Stability of Standard and Sample Solutions: 
Preparation of Sample Solutions: 
 Transfer about 66.6 mg of placebo of Pregabalin Tablets and add 20-ml from Stock 
Standard solution (0.3333 mg/ml of Pregabalin WS) to a 200 ml volumetric flask. 
Dissolve with the aid of sonication in dissolution medium to volume, and mix.  
 Analyze the prepared standard and sample solutions over three periods (Zero Time, 
after 3hr and after 24hr at a storage at room temperature) according to the test method 
of analysis for dissolution test of Pregabalin in Pregabalin Tablets. 
 Print out the Results. 
 
Data Analysis and Acceptance Criteria: The acceptable range for standard and sample 
solutions stability is typically between 98%-102% compared with the initial analysis of the 
standard and /sample solutions. 
 
4.11.2.6 Specificity/Placebo Interference  
Purpose: The purpose of this test is to demonstrate that the results are not unduly affected 
by placebo constituents. 
Procedure: 
Placebo Preparation: Prepare placebo of Pregabalin Tablets according to the formulation 
procedure of Pregabalin Tablets without addition of active ingredient. 
Standard Solution Preparation: Use the nominal standard solution for dissolution test.  
Nominal Placebo Solution Preparation: Dissolve 250 mg of Placebo in 900 ml of 
Dissolution Medium at 37
o
C. Filter portion of solution using 0.2 micron filter.  
 Inject the standard and sample solutions in the HPLC and record the results. 
 Determine the interference of placebo using the following formula: 
Interference % = 100*C*(AP/ASt)*V/L 
   Where, 
    C: is the concentration, in mg per ml, of the standard 
    AP: is the absorbance of the placebo 
    ASt: is the absorbance of the standard 
    V: is the volume, in ml, of the medium 
    L: is the label claim, in mg of the product 
 
Acceptance Criteria: The interference of Placebo should not exceed 2%. 
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4.11.2.7 Ruggedness (Intermediate Precision): 
Procedure: 
Standard Solution: Use the nominal standard solution (0.3333 mg/ml of Pregabalin WS) . 
This test was performed by analysis of the nominal standard solution by different analyst 
and on different days (matrix design). Inject the working standard solution at nominal 
concentration (0.3333 mg/ml of Pregabalin WS) using Chromatographic HPLC. 
Calculate the relative standard deviations (RSD) of the replicate readings. 
Acceptance Criteria: Verify that, the Relative Standard Deviation for the replicate readings 
is not more than 5.0%. 
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Part V Results and Discussion 
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5.0 Results and Discussion 
Summaries of the analysis results, Validation, and discussions are presented in this chapter: 
5.1 Selection of Pregabalin API 
Pregabalin was tested and analyzed according to its manufacturer test methods. All results 
are found to be within limits and conform to specifications, as illustrated in table 20. 
Table 22: Characteristics of Pregabalin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The COAs of excipients are attached in Appendix 1.  
 
 
 
 
Test Manufacturer Limits Results 
Assay 98.0-102.0% (on anhydrous bases)  98.6% 
Characteristics White Crystalline powder 
White 
Crystalline 
powder 
Particle size  
D (90) 
D (50)           
D (10) 
 
For Information 
 
812µm 
72µm 
7µm 
 
Identification (IR) conform to standard 
conform to 
standard 
Water Content NMT 0.50% 0.05% 
Residue on ignition NMT 0.10% 0.00% 
Specific Optical Rotation 
(ODB) 
+10.0 to +12.0 +11.8 
Bromide content Less than 50 ppm < 50ppm 
Heavy Metals Less than 10ppm < 10ppm 
Related Substances  
Impurity- III 
Impurity- IV 
Any other impurity 
Total impurities 
 
 
NMT 0.15% 
NMT 0.15% 
NMT 0.10% 
NMT 0.50% 
 
 
BDL 
BDL 
BDL 
BDL 
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5.2 Compatibility Study 
Spectra obtained from pure Pregabalin were found C-H from Alkane part, C-N and N-H 
from Amine group and O-C and O-H from Carboxyl group. 
 
As obtained in the next spectroscopy: 
 
Figure 20: Pregabalin pure Spectroscopy 
 
The results of previous spectroscopy is summarized and tabulated in Table 22. 
 
Table 23: Pregabalin Function group using FTIR results. 
 
 
 
 
 
 
 
F.G FTIR  
Range 
Pregabalin pure  
Alkane (C-H)s 2850-3000 2or3 bands 2954.68 
 Alkane (C-H)s 1000-1250 2895.33 
Amine (C-N)s 1550-1650 1162.62 
Amine (N-H)b 1210-1320 1643 
Carboxylic acid 
(O-C)s 
2500-3300 1278.11 
Carboxylic acid 
(O-H)s 
2500-3300 2600.72 
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In Case of Mixture of Magnesium Stearate and Pregabalin 
FT-IR spectroscopy of mixture shows very close spectra of the pure component as appears 
in the next spectra 
 
Figure 21: Spectroscopy of Mixture of Magnesium Stearate and Pregabalin 
 
The previous spectra show that the main bond in Pregabalin and the Magnesium Stearate 
mixture is very similar as shown in the next table  
Table 24: Pregabalin Function group using FTIR results 
 
Previous results indicate that there is no interference between Pregabalin and magnesium 
stearate (Table-21). There was no major change in peaks of Alkane (C-H), Amine (C-N), 
Amine (N-H) or Carboxylic Acid (O-C) in reference to the observed value of pure 
Pregabalin. . Slightly shifting in Carboxylic Acid (O-H) may refer to the presence of water 
in Magnesium Stearate. 
F.G 
FTIR 
Range 
Pregabalin pure 
Pregabalin, Mg. Stearate 
(1:1) 
Alkane (C-H)s 2850-3000 2or3 bands 2954.68 2955.02 
Alkane (C-H)s 1000-1250 2895.33 2917.28 
Amine (C-N)s 1550-1650 1162.62 1162.56 
Amine (N-H)b 1210-1320 1643 1644.37 
Carboxylic acid 
(O-C)s 
2500-3300 1278.11 1278.2 
Carboxylic acid 
(O-H)s 
2500-3300 2600.72 2527.83 
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In Case of Mixture of Talc and Pregabalin 
FT-IR spectroscopy of mixture shows very close spectra of the pure component as appears 
in the next spectra 
 
Figure 22: Spectroscopy of Mixture of Talc and Pregabalin 
 
The previous spectra show that the main bond in pure Pregabalin and in the mixture is very 
similar as shown in the next table 
 
Table 25: Pregabalin Function group using FTIR results 
 
 
 
 
 
 
 
 
 
 
Previous results indicate that there is no interference between Pregabalin and Talc (Table-
22). There was no major change in peaks of Alkane (C-H), Amine (C-N), Amine (N-H), 
Carboxylic Acid (O-C) and Carboxylic Acid (O-H) in reference to the observed value of 
pure Pregabalin. 
 
F.G FTIR  
Range 
Pregabalin pure  Pregabalin, Talc (1:1) 
Alkane (C-H)s 2850-3000  2954.68 2954.97 
 Alkane (C-H)s 2850-3000 2895.33 2920.67 
Amine (C-N)s 1550-1650 1162.62 11362.45 
Amine (N-H)b 1210-1320 1643 1645.25 
Carboxylic acid 
(O-C)s 
2500-3300 1278.11 1278.29 
Carboxylic acid 
(O-H)s 
2500-3300 2600.72 2601.5 
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In Case of Mixture of Microcrystalline Cellulose (Avicel) and Pregabalin 
FT-IR spectroscopy of mixture shows very close spectra of the pure component as appears 
in the next spectra 
 
Figure 23: Spectroscopy of Mixture of Avicel and Pregabalin 
 
The previous spectra shows that the main bond in pure Pregabalin and in the binary mixture 
is very similar as shown in the next table. 
Table 26: Pregabalin Function group using FTIR results 
 
 
 
 
 
 
 
 
 
 
Previous results indicate that there is no interference between Pregabalin and Avicel (Table-
23). There was no major change in peaks of Alkane (C-H), Amine (C-N), Amine (N-H), 
Carboxylic Acid (O-C) and Carboxylic Acid (O-H) in reference to the observed value of 
pure Pregabalin. 
 
 
 
F.G FTIR  
Range 
Pregabalin pure  Pregabalin, Avicel 
PH 102 (1:1) 
Alkane (C-H)s 2850-3000 2or3 bands 2954.68 2954.82 
 Alkane (C-H)s 1000-1250 2895.33 2895.58 
Amine (C-N)s 1550-1650 1162.62 1162.45 
Amine (N-H)b 1210-1320 1643 1644.92 
Carboxylic acid 
(O-C)s 
2500-3300 1278.11 1278.2 
Carboxylic acid 
(O-H)s 
2500-3300 2600.72 2601.47 
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In Case of Mixture of Starch and Pregabalin 
FT-IR spectroscopy of mixture shows very close spectra of the pure component as appears 
in the next spectra. 
 
Figure 24: Spectroscopy of Mixture of Starch and Pregabalin 
 
The previous spectra show that the main bond in pure Pregabalin and in the binary mixture 
is very similar as shown in the next table. 
 
Table 27: Pregabalin Function group using FTIR results 
 
 
 
 
 
 
 
 
 
Previous results indicate that there is no interference between Pregabalin and Starch (Table-
24). There was no major change in peaks of Alkane (C-H), Amine (C-N), Amine (N-H), 
Carboxylic Acid (O-C) and Carboxylic Acid (O-H) in reference to the observed value of 
pure Pregabalin. 
As a summary the data obtained from FTIR Compatibility study clearly indicates 
insignificant changes in spectra obtained from physical mixture of Pregabalin and selected 
excipients. And all results of Compatibility study indicate that there is no interference 
between Pregabalin and other excipients as appeared in Figures (20-24) and Tables (18-22). 
There was no major change in peaks of Alkane (C-H), Amine (C-N), Amine (N-H), 
Carboxylic Acid (O-C) and Carboxylic Acid (O-H) in reference to the observed value of 
pure Pregabalin. 
F.G FTIR  
Range 
Pregabalin pure  Pregabalin, Starch 1500 (1:1) 
Alkane (C-H)s 2850-3000 2or3 bands 2954.68 2954.77 
 Alkane (C-H)s 1000-1250 2895.33 2921.24 
Amine (C-N)s 1550-1650 1162.62 1162.23 
Amine (N-H)b 1210-1320 1643 1644.76 
Carboxylic acid 
(O-C)s 
2500-3300 1278.11 1278.17 
Carboxylic acid 
(O-H)s 
2500-3300 2600.72 2601.46 
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5.3 Analysis of Pre-formulation formulae 
The results of physical analysis of Pregabalin blends are shown in Table 28; the tablets 
physical characteristics are summarized in table 29.  
 
Table 28: Pre-formulation Powder Blends Physical Characteristics 
 
Table 29:  Pre-formulation Compressed Tablets Physical Characteristics  
 
From the results shown in tables (28, 29), it is obvious that all powder blends have fair to 
passable flowability; Pregabalin with lubricant alone (F-1) has poor compaction 
characteristics. It is clear that the increase of filler/binder percentage from 33% to 45% (F-2 
→ F-5) improved the compaction characters of powder mixture. The use of starch maize as 
disintegrant caused tablets to cap (F-2, F-3, F-7), while use of pregelatinized starch instead 
of maize starch, lead  get smooth and intact tablets (F-5, F-6); this may be due to the binding 
effect of pregelatinized starch in direct compression methods.  
Pre-formulation properties 
Formula Tapped Density Untapped Density 
Flowability 
"Hausner ratio" 
Carr`s index 
(compressibility) 
F-1 ----- ---- ---- ---- 
F-2 0.658 0.531 1.24 19.3% 
F-3 0.663 0.529 1.30 20.2% 
F-4 0.660 0.538 1.23 18.5% 
F-5 0.650 0.522 1.25 19.7% 
F-6 0.648 0.523 1.24 19.3% 
F-7 0.641 0.519 1.24 19.0% 
F-8* 0.650 0.522 1.25 19.7% 
* F-5 and F-8 are the same formula but compressed under different parameter and different punches. 
Compressed Tablet properties 
Formula 
Hardness 
(Kgf) 
Friability 
(w/w) % 
Average 
weight (mg) 
Thickness 
(mm) 
Dis. Time 
(seconds) 
Tablet 
Appearance 
F-1 0.0 100% --- --- --- No tablet was 
formed 
F-2 5.5-7.9 0.9% 579 4.59 18 sec. Capping 
F-3 2.1-4.5 1.3% 540 4.60 15 sec. Capping 
F-4 3.5-5.0 0.9% 652 4.32 25 sec. Uniform and 
Smooth 
F-5 9.0-12.5 0.3% 662 4.95 60 sec. Uniform and 
Smooth 
F-6 3.5-4.8 0.8% 668 4.81 27 sec. Uniform and 
Smooth 
F-7 4.5-5.5 0.6% 663 6.89 22 sec. Capping 
F-8* 8.0-10.6 0.4% 660 4.88 54 sec. Uniform and 
Smooth 
* F-5 and F-8 are the same formula but compressed under different parameter and different punches. 
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Furthermore, F3 and F4 formulae have low disintegration times (15 to 25 seconds) and high 
friability values (about or more than 1.0%).   
Comparison between Formulae F-5 and F-6 as the candidate ones, we excluded F-6 from 
further study, because of the low hardness and disintegration time of compressed tablets that 
may cause to partially disintegration in the mouth during swallow. 
Formula F-5 has the best physical and mechanical properties and promising candidate for 
further studies. 
Formula (F-5) as optimized formula was selected according to different parameters from 
pre-formulation parameter until to obtain tablet properties as Flowability, hardness, 
disintegration, tablet appearance, for that we can transfer to the implementation and 
evaluation stages as shown in the next section. 
5.4 Implementation of Selected Formula 
Pregabalin tablets, with two strengths 300mg tablet and 75mg tablet were prepared using the 
same component ratio of selected formula (F5). 
About 2000 tablets were compressed and coated from Pregabalin 300mg strength, and about 
8000 tablets were compressed and produced from Pregabalin 75mg strength. 
The same general manufacturing procedure was applied.  
5.5 Selection of packaging raw material 
The coated tablets were filled in PVC-Alum blisters, and all evaluation tests, such as sealing 
test and stability study were performed to evaluate the efficiency of PVC Blister as 
packaging material for Pregabalin tablet. 
5.6 Pregabalin Tablets Evaluation 
The two implemented batches of Pregabalin tablets (75mg and 300mg) were tested 
according to the developed and validated test methods. All results are summarized as the 
following: 
 
 
General Appearance: 
The general appearance (color, shape, dimension and appearance) of the formulated tablets 
was inspected and tested; all results were recorded and tabulated in the next tables. 
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Table 30: Evaluation results - Physical properties and general appearance 
Tests Acceptance Criteria 
Results 
Pre. 300mg 
Results 
Pre. 75mg 
Color & Odor 
White / off-white and Characteristic 
Odor 
White / off-
white 
White / off-
white 
Shape Oblong Oblong Oblong 
Width 
9.1 (+/- 0.2) mm (for 300mg strength) 
5.1 (+/- 0.2) mm (for 75mg strength) 
9.1 5.1 
Thickness 
4.7 (+/- 0.3) mm (for 300mg strength) 
3.1 (+/- 0.2) mm (for 75mg strength) 
4.7 3.1 
Appearance of 
Coat 
Smooth & Homogeneous 
Smooth & 
Homogeneous 
Smooth & 
Homogeneous 
Table 31: Evaluation results – Tablet Thickness 
Tab. No. 1 2 3 4 5 6 7 8 9 10 Avg. SD 
Per. 300mg 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 0.0 
Pre. 75mg 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 0.0 
 
 
Hardness: 
The force required to cause fracture was recorded. It is repeated for 10 tablets and the 
measured values are averaged, all results are within limits as tabulated in table (32). 
Table 32: Hardness Results 
Tab. No. 1 2 3 4 5 6 7 8 9 10 Avg. SD 
300mg 9.0 9.6 10.2 9.9 10.5 11.0 11.2 9.6 10.2 9.1 10.0 0.7 
75mg 8.3 9.6 8.8 9.5 9.9 8.4 10.2 7.9 9.8 9.5 9.0 0.7 
Acceptance Criteria: NLT 5.0 Kgf 
 
 
Friability 
The friability results are shown in Table 33, all results are within limits. 
 
Table 33: Friability Results 
Test Acceptance Criteria Results 
Pre. 300mg 
Results 
Pre. 75mg 
Friability NMT 1.0%, 100 rounds 0.3% 0.1% 
 
Uniformity of dosage units: 
Results of uniformity of dosage units are shown in Tables 34, 35.  
 
Table 34: Uniformity of dosage units result for Pregabalin 300 mg Tablets 
Product  Pregabalin 75 mg Tablets 
BN. 150915 
Exp. Date  09/2017 
Theoretical weight 167.5 mg 
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Parameter 
& Tablet No. 
Weight 
(mg) 
Content of Pregabalin in each unit 
expressed as a percent to label claim [%] 
1 170.4 101.7 
2 176.7 105.5 
3 166.5 99.4 
4 175.5 104.8 
5 166.6 99.5 
6 171.1 102.1 
7 165.1 98.6 
8 175.3 104.7 
9 172.0 102.7 
10 172.3 102.9 
X 
(Average) 
171.2 102.2 
T (Target test sample amount at 
time of manufacture) 
100.0  
SD (Standard Deviation) 2.3 
M 101.5 
k  
AV (Acceptance Value ) 
where (AV = | M-X+k.SD) NMT 15 
6.2 
Result: Pass According to USP, No need to other stage. 
 
Table 35: Uniformity of dosage units result for Pregabalin 75 mg Tablets 
Product  Pregabalin 300 mg Tablets 
BN. 150914 
Exp. Date  09/2017 
Theoretical weight 670.0 mg 
 
Parameter 
 & Tablet No. 
Weight 
(mg) 
Content of Pregabalin in each unit 
expressed as a percent to label claim [%] 
1 677.9 101.2 
2 684.7 102.2 
3 678.3 101.2 
4 703.2 105.0 
5 686.0 102.4 
6 682.7 101.9 
7 685.9 102.4 
8 632.9 94.5 
9 675.4 100.8 
10 687.9 102.7 
 
(Average) 
679.5 101.4 
T (Target test sample amount at 
time of manufacture) 
100.0 
SD (Standard Deviation) 2.7 
M 101.4 
k 2.4 
AV (Acceptance Value ) 
where (AV = | M-X+k.SD) NMT 15 
6.5 
Result: Pass According to USP, No need to other stage. 
All results of Acceptance Values (AV) are within the acceptable limits. 
X
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Disintegration Test: 
All Pregabalin 300mg and Pregabalin 75mg tablets disintegrate within two minutes. 
Acceptance Criteria: All tablets should disintegrate within 15 minutes. 
 
Dissolution for routine testing: 
Dissolution rate studies: The dissolution rate was carried out by using USP Type II (paddle 
type) dissolution apparatus. 
  
Table 36: Dissolution results 
Batch\ 
Vessel No. 
1 2 3 4 5 6 Average SD 
F-5, 300 91.4 91.1 105.5 91.4 96.6 90.9 94.5% 5.8 
F-5, 75 104.6 101.6 105.9 101.8 100.7 101.1 102.6% 2.1 
Acceptance 
Criteria 
Not Less than 75.0 % (Q) of the labeled amount of Pregabalin is dissolved 
within 30 minutes 
 
Assay and Related Tests 
 
Table 37: Results of chemical tests for Pregabalin Finished products 
  Acceptance Criteria 
Results 
F-5, 300 
Results 
F-5, 75 
Assay    
 -Pregabalin 90.0-110.0 %                          100.9% 99.0% 
Related Substances:   
-Individual impurities. 
-Total Impurities. 
 
NMT 0.2% 
NMT 1.0% 
BDL 
BDL 
BDL 
BDL 
 
 
5.7 Biowaiver Study 
5.7.1 Results of Dissolution Profiles  
Dissolution profiles were performed for both implemented batches (Pregabalin 300mg and 
75mg) versus reference product (Lyrica 300mg and 75mg Capsules) in different dissolution 
media: 0.06N HCl, Acetate Buffer pH 4.5 and Phosphate Buffer pH 6.8. The data are 
reported in Tables (36-41), and the summary of results is illustrated in tables (41-43) and 
figures (25-30). 
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5.7.1.1 Dissolution Profile data for Pregabalin 75mg tablets and Lyrica 75mg Capsules 
 
Table 38: Dissolution Profile data for Pregabalin 75mg capsules and tablets in 0.06N HCl 
Test conditions: 
Medium 0.06N HCl Volume 900 
mL 
Apparatus II (Paddle) Rotational 
Speed: 
50 
RPM 
 
Data of dissolution profile for Pregabalin 75mg 
Dissolution Media 0.06N HCl 
Pregabalin 
STD 
Dissolution 
time 
Response 
Area (F5) 
Dissolution 
results (F5) 
Response 
Area 
(Lyrica) 
Dissolution 
results 
(Lyrica) 
F5 STD 10 96126 94.1% 94580 96.5% 
102480 10 97061 95.0% 99440 101.5% 
102136 10 91602 89.7% 96215 98.2% 
102184 10 103322 101.2% 94753 96.7% 
101677 10 81011 79.3% 95658 97.6% 
Avg. 
102119 
10 98858 96.8% 97207 99.2% 
 15 102932 100.8% 96092 98.1% 
 15 105060 102.9% 99526 101.6% 
 15 104983 102.8% 98553 100.6% 
Lyrica STD 15 102691 100.6% 99209 101.3% 
97980 15 95776 93.8% 98887 100.9% 
98198 15 102849 100.7% 97585 99.6% 
97936 30 106771 104.6% 98323 100.4% 
97774 30 103499 101.4% 98221 100.3% 
Avg.  97972 30 108112 105.9% 98796 100.8% 
 
30 103958 101.8% 99096 101.1% 
 
30 102881 100.7% 98220 100.3% 
 
30 103255 101.1% 97923 99.9% 
 
45 106841 104.6% 98218 100.3% 
 
45 104793 102.6% 98335 100.4% 
 
45 108501 106.2% 98923 101.0% 
 
45 106891 104.7% 98191 100.2% 
 
45 102215 100.1% 98033 100.1% 
 
45 103753 101.6% 97824 99.8% 
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Table 39: Dissolution Profile data for Pregabalin 75mg capsules and tablets in Acetate Buffer pH 4.5 
Test conditions: 
Medium Acetate 
Buffer pH4.5 
Volume 900 
mL 
Apparatus II (Paddle) Rotational 
Speed: 
50 
RPM 
 
Data of dissolution profile for Pregabalin 75mg 
Dissolution Media Acetate Buffer PH4.5 
Pregabalin 
STD 
Dissolution 
time 
Response 
Area (F5) 
Dissolution 
results (F5) 
Response 
Area 
(Lyrica) 
Dissolution 
results 
(Lyrica) 
F5 STD 10 80314 78.4% 159638 88.3% 
101297 10 77204 75.4% 156880 86.8% 
104407 10 96166 93.9% 166399 92.1% 
102310 10 79290 77.4% 172978 95.7% 
101590 10 86953 84.9% 178595 98.8% 
Avg.  102401 10 87156 85.1% 163046 90.2% 
 15 87386 85.3% 171049 94.6% 
 
15 97833 95.5% 171955 95.1% 
 
15 100722 98.4% 174482 96.5% 
Lyrica STD 15 86738 84.7% 179724 99.4% 
180069 15 96124 93.9% 182784 101.1% 
179052 15 98772 96.5% 179810 99.5% 
179750 30 98469 96.2% 180649 99.9% 
Avg.  180740 30 104090 101.6% 181270 100.3% 
 
30 102147 99.8% 183250 101.4% 
 
30 100316 98.0% 180589 99.9% 
 
30 105930 103.4% 183674 101.6% 
 
30 103672 101.2% 183262 101.4% 
 
45 103799 101.4% 183592 101.6% 
 
45 103978 101.5% 181436 100.4% 
 
45 102626 100.2% 183233 101.4% 
 
45 105254 102.8% 180719 100.0% 
 
45 104607 102.2% 181888 100.6% 
 
45 104557 102.1% 182620 101.0% 
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Table 40: Dissolution Profile data for Pregabalin 75mg capsules and tablets in Phosphate Buffer pH 6.8 
Test conditions: 
Medium Phosphate 
Buffer pH 6.8 
Volume 900 
mL 
Apparatus II (Paddle) Rotational 
Speed: 
50 
RPM 
 
Data of dissolution profile for Pregabalin 75mg 
Dissolution Media Phosphate Buffer PH6.8 
Pregabalin 
STD 
Dissolution 
time 
Response 
Area(F5) 
Dissolution 
results (F5) 
Response 
Area (Lyrica) 
Dissolution 
results 
(Lyrica) 
F5 STD 10 78050 76.2% 166031 91.7% 
101436 10 79647 77.8% 166712 92.0% 
100926 10 97237 95.0% 144813 80.0% 
102348 10 78937 77.1% 154295 85.2% 
101584 10 80140 78.3% 164757 91.0% 
Avg.  101574 10 80171 78.3% 160033 88.4% 
 15 92169 90.0% 173643 95.9% 
 
15 91980 89.8% 178367 98.5% 
 
15 105657 103.2% 169718 93.7% 
Lyrica STD 15 93369 91.2% 176982 97.7% 
180161 15 93763 91.6% 173317 95.7% 
180583 15 90767 88.6% 138328 76.4% 
181974 30 103938 101.5% 185828 102.6% 
181785 30 96320 94.1% 186048 102.7% 
Avg. 181126 30 105603 103.1% 181037 100.0% 
 
30 104241 101.8% 181324 100.1% 
 
30 99349 97.0% 178660 98.6% 
 
30 97191 94.9% 179581 99.1% 
 
45 108806 106.3% 185855 102.6% 
 
45 96647 94.4% 185632 102.5% 
 
45 105715 103.2% 179929 99.3% 
 
45 108858 106.3% 182223 100.6% 
 
45 99186 96.9% 180907 99.9% 
 
45 98221 95.9% 181737 100.3% 
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5.7.1.1 Dissolution Profile data for Pregabalin 300mg tablets and Lyrica 300mg Capsules  
 
Table 41: Dissolution Profile data for Pregabalin 300mg capsules and tablets in 0.06N HCl 
Test conditions: 
Medium 0.06N HCl Volume 900 
mL 
Apparatus II (Paddle) Rotational 
Speed: 
50 
RPM 
 
Data of dissolution profile for Pregabalin 300mg 
Dissolution Media 0.06N HCL 
Pregabalin 
STD 
Dissolution 
time 
Response 
Area (F5) 
Dissolution 
Area (F5) 
Response 
Area 
(Lyrica) 
Dissolution 
results 
(Lyrica) 
F5 STD 10 304397 73.9% 279689 95.9% 
410344 10 296660 72.1% 280675 96.2% 
413031 10 378433 91.9% 272800 93.5% 
411849 10 316900 77.0% 270292 92.7% 
Avg.  411741 10 314696 76.4% 265325 91.0% 
 10 303098 73.6% 264638 90.7% 
 
15 388086 94.3% 283916 97.3% 
Lyrica STD 15 347478 84.4% 289622 99.3% 
294033 15 393724 95.6% 
279436 95.8% 
290970 15 394912 95.9% 
280878 96.3% 
291015 15 373659 90.8% 
282238 96.8% 
290773 15 356618 86.6% 
278267 95.4% 
Avg.  291698 30 397631 96.6% 
294800 101.1% 
 
30 412645 100.2% 
291630 100.0% 
 
30 402771 97.8% 289387 99.2% 
 
30 402478 97.8% 290575 99.6% 
 
30 402273 97.7% 289988 99.4% 
 
30 413730 100.5% 291956 100.1% 
 
45 404212 98.2% 293076 100.5% 
 
45 416548 101.2% 291202 99.8% 
 
45 400797 97.3% 290963 99.7% 
 
45 402912 97.9% 290352 99.5% 
 
45 401106 97.4% 292947 100.4% 
 
45 415559 100.9% 291207 99.8% 
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Table 42: Dissolution Profile data for Pregabalin 300mg capsules and tablets in Acetate Buffer pH 4.5 
Test conditions: 
Medium Acetate 
Buffer pH 4.5 
Volume 900 
mL 
Apparatus II (Paddle) Rotational 
Speed: 
50 
RPM 
 
Data of dissolution profile for Pregabalin 300mg 
Dissolution Media Acetate Buffer 4.5 
Pregabalin 
STD 
Dissolution 
time 
Response 
Area (F5, 
300 mg) 
Response 
Area (F5, 
300 mg) 
Response 
Area 
(Lyrica, 300 
mg) 
Dissolution 
results 
(Lyrica, 300 
mg) 
F5 STD 10 288565 69.9% 648252 91.0% 
412833 10 312608 75.7% 638509 89.7% 
412987 10 261059 63.2% 577614 81.1% 
414233 10 289999 70.2% 622463 87.4% 
412188 10 303518 73.5% 576747 81.0% 
Avg.  413060 10 341769 82.7% 618778 86.9% 
 15 325157 78.7% 660780 92.8% 
 
15 365802 88.6% 672888 94.5% 
 
15 361339 87.5% 610981 85.8% 
Lyrica STD 15 330846 80.1% 649315 91.2% 
735809 15 364754 88.3% 608804 85.5% 
733348 15 364878 88.3% 659182 92.6% 
731075 30 375392 90.9% 689192 96.8% 
648252 30 396953 96.1% 697620 98.0% 
Avg. 712121 30 408413 98.9% 665478 93.5% 
 
30 374296 90.6% 696077 97.7% 
 
30 412544 99.9% 669864 94.1% 
 
30 397018 96.1% 705375 99.1% 
 
45 397647 96.3% 704977 99.0% 
 
45 397886 96.3% 704834 99.0% 
 
45 410425 99.4% 686731 96.4% 
 
45 396555 96.0% 706567 99.2% 
 
45 411990 99.7% 682073 95.8% 
 
45 400770 97.0% 699422 98.2% 
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Table 43: Dissolution Profile data for Pregabalin 300mg capsules and tablets in Phosphate Buffer pH 6.8 
Test conditions: 
Medium Phosphate 
Buffer pH 6.8 
Volume 900 
mL 
Apparatus II (Paddle) Rotational 
Speed: 
50 
RPM 
 
Data of dissolution profile for Pregabalin 300mg 
Dissolution Media Phosphate Buffer 6.8 
Pregabalin 
STD 
Dissolution 
time 
Response 
Area (F5, 
300 mg) 
Response 
Area (F5, 
300 mg) 
Response 
Area 
(Lyrica, 300 
mg) 
Dissolution 
results 
(Lyrica, 300 
mg) 
F5 STD 10 285586 69.1% 612896 83.2% 
412833 10 276586 67.0% 643429 87.4% 
412987 10 302019 73.1% 645995 87.7% 
414233 10 284134 68.8% 642968 87.3% 
412188 10 256454 62.1% 622618 84.6% 
Avg. 413060 10 254285 61.6% 659358 89.6% 
 15 302760 73.3% 648352 88.1% 
 
15 335727 81.3% 690028 93.7% 
Lyrica STD 15 372147 90.1% 662458 90.0% 
739033 15 327984 79.4% 689209 93.6% 
740162 15 338026 81.8% 667207 90.6% 
734646 15 336058 81.4% 682886 92.8% 
731153 30 377440 91.4% 682704 92.7% 
Avg.  736248 30 376149 91.1% 708113 96.2% 
 30 435745 105.5% 706277 95.9% 
 
30 377603 91.4% 704593 95.7% 
 
30 398975 96.6% 704914 95.7% 
 
30 375443 90.9% 713632 96.9% 
 
45 399793 96.8% 694198 94.3% 
 
45 402200 97.4% 709030 96.3% 
 
45 440199 106.6% 710550 96.5% 
 
45 401996 97.3% 703948 95.6% 
 
45 408589 98.9% 708811 96.3% 
 
45 400829 97.0% 715767 97.2% 
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5.7.2 Summaries of dissolution profiles  
The dissolution results were calculated from the data obtained in the previous section 5.7.1. 
The averages and the relative standard deviations at each time interval were calculated and 
tabulated in the following tables. 
 
5.7.2.1 For Pregabalin 75mg Tablets and Capsules 
 
 Dissolution Profile in 0.06N HCl 
Table 44: Dissolution profile results of Pregabalin 75mg Tablets vs Lyrica 75mg Capsules in 0.06N HCl 
Time Dissolution medium 0.06N HCl 
Pregabalin 75mg Tablet (F5) Lyrica Capsules 75mg 
Batch No.: F5, 75 
n=6 
Batch No.:  
n=6 
Release % SD (RSD %) Release % SD (RSD %) 
0 0.0% 0.0 (0.0%) 0.0% 0.0 (0.0%) 
10 92.7% 6.9 (7.4%) 98.3% 1.9 (1.9%) 
15 100.3% 3.3 (3.3%) 100.3% 1.3 (1.3%) 
30 102.6% 2.1 (2.0%) 100.5% 0.5 (0.5%) 
45 103.3% 2.3 (2.2%) 100.3% 0.4 (0.4%) 
 
The percent released for both Test and Reference products in 0.06N exceeds 85% in 15 
minutes, which means there is no need to calculate the similarity factor (f2), and the two 
products are considered similar. 
 
 
 
Figure 25: Dissolution profile of Pregabalin 75mg Tablets versus Lyrica 75 Capsules in 0.06N HCl  
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 Dissolution Profile in Acetate buffer pH 4.5  
 
 
Table 45: Dissolution profile results of Pregabalin 75mg Tablets vs Lyrica 75mg Capsules in 
Acetate buffer pH 4.5 
Time Dissolution medium Acetate buffer pH 4.5 
Pregabalin 75mg Tablet (F5) Lyrica Capsules 75mg 
Batch No.: F5, 75 
n=6 
Batch No.:  
n=6 
Release % SD (RSD %) Release % SD (RSD %) 
0 0.0% 0.0 (0.0%) 0.0% 0.0 (0.0%) 
10 82.50% 6.9 (8.4%) 92.00% 4.6 (5.0%) 
15 92.40% 5.9 (6.4%) 97.70% 2.7 (2.8%) 
30 100.00% 2.6 (2.6%) 100.80% 0.8 (0.8%) 
45 101.70% 0.9 (0.9%) 100.70% 0.6 (0.6%) 
 
The percent released for both Test and Reference products in Acetate buffer pH 4.5 exceeds 
85% in 15 minutes, which means there is no need to calculate the similarity factor (f2), and 
the two products are considered similar. 
 
Figure 26: Dissolution profile of Pregabalin 75mg Tablets versus Lyrica 75 Capsules in Acetate buffer pH 4.5  
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 Dissolution profile in Phosphate buffer pH 6.8  
  
 
Table 46: Dissolution profile results (Pregabalin 75mg Tablets vs. Lyrica 75mg Capsules) in Phosphate buffer 
pH 6.8 
Time Dissolution medium Phosphate buffer pH 6.8 
Pregabalin 75mg Tablet (F5) Lyrica Capsules 75mg 
Batch No.: F5, 75 
n=6 
Batch No.:  
n=6 
Release % SD (RSD %) Release % SD (RSD %) 
0 0.0% 0.0 (0.0%) 0.0% 0.0 (0.0%) 
10 82.50% 7.2 (8.7%) 92.00% 4.7 (5.1%) 
15 92.40% 5.4 (5.8%) 97.70% 8.3 (8.5%) 
30 100.00% 3.9 (3.9%) 100.80% 1.7 (1.7%) 
45 101.70% 5.4 (5.3%) 100.70% 1.4 (1.4%) 
 
The percent released for both Test and Reference products in Phosphate buffer pH 6.8 
exceeds 85% in 15 minutes, which means there is no need to calculate the similarity factor 
(f2), and the two products are considered similar. 
 
 
 
Figure 27: Dissolution profile of Pregabalin 75mg Tablets versus Lyrica 75 Capsules in Phosphate buffer pH 
6.8  
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5.7.2.2 For Pregabalin 300mg Tablets and Capsules 
 
 Dissolution Profile in 0.06N HCl  
  
 
Table 47: Dissolution profile results: Pregabalin 300mg Tablets vs Lyrica 300mg Capsules in 0.06N HCl) 
Time Dissolution medium 0.06 HCl 
Pregabalin 300mg Tablet (F5) Lyrica Capsules 300mg 
Batch No.: F5 300 
n=6 
Batch No.:  
n=6 
Release % SD (RSD %) Release % SD (RSD %) 
0 0.0% 0.0 (0.0%) 0.0% 0.0 (0.0%) 
10 77.50% 7.3 (9.4%) 93.30% 4.2 (4.5%) 
15 91.30% 4.5 (4.9%) 96.80% 3.8 (3.9%) 
30 98.40% 1.5 (1.5%) 99.90% 2.3 (2.3%) 
45 98.80% 1.8 (1.8%) 100.00% 1.4 (1.4%) 
 
The percent released for both Test and Reference products in 0.06N HCl exceeds 85% in 15 
minutes, which means there is no need to calculate the similarity factor (f2), and the two 
products are considered similar 
 
Figure 28: Dissolution profile of Pregabalin 300mg Tablets versus Lyrica 300 Capsules in 0.06N HCl  
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 Dissolution Profile in Acetate buffer pH 4.5  
  
 
Table 48: Dissolution profile results (Pregabalin 300mg Tablets versus Lyrica 300 Capsules) in Acetate buffer 
pH 4.5 
Time Dissolution medium Acetate buffer pH 4.5 
Pregabalin 75mg Tablet (F5) Lyrica Capsules 75mg 
Batch No.: F5 300 
n=6 
Batch No.:  
n=6 
Release % SD (RSD %) Release % SD (RSD %) 
0 0.0% 0.0 (0.0%) 0.0% 0.0 (0.0%) 
10 72.50% 6.6 (9.1%) 86.00% 2.3 (2.7%) 
15 85.20% 4.6 (5.4%) 90.40% 2.3 (2.5%) 
30 95.40% 3.9 (4.0%) 96.50% 1.4 (1.5%) 
45 97.50% 1.7 (1.7%) 97.90% 1.0 (1.0%) 
 
The percent released for both Test and Reference products in Acetate buffer pH 4.5 exceeds 
85% in 15 minutes, which means there is no need to calculate the similarity factor (f2), and 
the two products are considered similar.   
 
Figure 29: Dissolution profile of Pregabalin 300mg Tablets versus Lyrica 300 Capsules in Acetate buffer pH 
4.5  
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 Dissolution Profile in Phosphate buffer pH 6.8  
  
 
Table 49: Dissolution profile results (F-5, 300mg/ Phosphate buffer pH 6.8) 
Time Dissolution medium Phosphate buffer pH 6.8 
Pregabalin 300mg Tablet (F5) Lyrica Capsules 300mg 
Batch No.:  
n=6 
Batch No.: F5 300 
n=6 
Release % SD (RSD %) Release % SD (RSD %) 
0 0.0% 0.0 (0.0%) 0.0% 0.0 (0.0%) 
10 70.00% 4.4 (6.2%) 86.60% 2.3 (2.6%) 
15 85.10% 6.8 (8.0%) 91.50% 2.3 (2.5%) 
30 94.50% 5.8 (6.1%) 95.50% 1.4 (1.5%) 
45 99.00% 3.8 (3.8%) 96.00% 1.0 (1.0%) 
 
The percent released for both Test and Reference products in Phosphate buffer pH 6.8 
exceeds 85% in 15 minutes, which means there is no need to calculate the similarity factor 
(f2), and the two products are considered similar. 
Figure 30: Dissolution profile of Pregabalin 300mg Tablets versus Lyrica 300 Capsules in Phosphate buffer 
pH 6.8  
As a summary, the data obtained indicates that the developed Pregabalin Tablets and the 
reference Lyrica Capsules are similar in all aspects and considered bioequivalent. 
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5.8 Stability Study 
The formulations F5, 300 and F5, 75 were stored at different storage conditions, at long term 
condition (25
o
C ± 2
o
C/ 60% RH± 5% RH), at intermediate conditions (30
o
C ±2
o
C/ 65%RH± 
5%RH) and at accelerated conditions (40
o
C ± 2
o
C / 75RH± 5%RH), the stability samples 
were analyzed at zero time, 14 days and 30 days as schedule in the methodology stability 
section.  
The stability results are tabulated in Tables (48-56). 
 
 
5.8.1 Pregabalin Tablet 300mg (F5, 300) Stability Results 
 
Table 50: Stability results of Pregabalin 300mg @ 25
o
C ± 2
o
C/ 60% RH± 5% RH 
Characteristics Acceptance Criteria @ initial time After 14 days After 30 days 
Appearance 
Oblong white tablet, 
Characteristic Odor with 
smooth and homogeneous 
coating 
Conforms Conforms Conforms 
Length 19.1 ± 0.2 mm 19.1 - - 
Width 9.1  ± 0.2 mm 9.1 - - 
Thickness 
4.2  ± 0.2 mm 
 
4.2 - - 
Hardness 6.0-12.0 Kgf  11.1 11.0 10.7 
Friability NMT 1.0%, 100 rounds 0.3% - - 
Dissolution Test Ref. (In-House)    
Pregabalin 
Not Less than 75.0 % (Q) of the 
labeled amount of Pregabalin  is 
dissolved within 30 minutes 
102.0% 99.0% 98.0% 
Assay Ref. (In-House)    
Pregabalin 90.0-110.0 %                          100.9% 102.5% 101.2% 
Related 
Substances 
Ref. (In-House)    
Individual 
impurities. 
Total Impurities. 
NMT 0.2% 
 
NMT 1.0% 
N.D 
 
N.D 
0.0% 
 
0.0% 
0.0% 
 
0.0% 
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Table 51: Stability results of Pregabalin 300mg @ 30
o
C ± 2
o
C/ 65% RH± 5% RH 
Characteristics Acceptance Criteria @ initial time After 14 days After 30 days 
Appearance 
Oblong white tablet, 
Characteristic Odor with smooth 
and homogeneous coating 
Conform Conform Conform 
Length 
Width 
19.1 ± 0.2 mm 
9.1  ± 0.2 mm 
19.1 
9.1 
- 
- 
- 
- 
Thickness 
4.2 (+/- 0.2) mm 
 
4.2 - - 
Hardness 6.0-12.0 Kgf  11.1 10.5 10.5 
Friability NMT 1.0%, 100 rounds 0.3% - - 
Dissolution Test Ref. (In-House)    
Pregabalin 
Not Less than 75.0 % (Q) of the 
labeled amount of Pregabalin  is 
dissolved within 30 minutes 
102.0% 98.9% 99.0% 
Assay Ref. (In-House)    
Pregabalin 90.0-110.0 %                          100.9% 102.3% 102.0% 
Related 
Substances 
Ref. (In-House)    
Individual 
impurities. 
Total Impurities. 
NMT 0.2% 
NMT 1.0% 
N.D 
N.D 
0.0% 
0.0% 
0.0% 
0.0% 
 
Table 52: Stability results of Pregabalin 300mg @ 40
o
C ± 2
o
C/ 75RH± 5% RH 
Characteristics Acceptance Criteria @ initial time After 14 days After 30 days 
Appearance 
Oblong white tablet, Characteristic 
Odor with smooth and 
homogeneous coating 
Conform Conform Conform 
Length 
Width 
19.1 ± 0.2 mm 
9.1  ± 0.2 mm 
19.1 
9.1 
- 
- 
- 
- 
Thickness 
4.2 (+/- 0.2) mm 
 
4.2 - - 
Hardness 6.0-12.0 Kgf  11.1 11.3 11.1 
Friability NMT 1.0%, 100 rounds 0.3% - - 
Dissolution Test Ref. (In-House)    
Pregabalin 
Not Less than 75.0 % (Q) of the 
labeled amount of Pregabalin  is 
dissolved within 30 minutes 
102.0% 95.2% 96.0% 
Assay Ref. (In-House)    
Pregabalin 90.0-110.0 %                          100.9% 101.7% 101.2% 
Related 
Substances 
Ref. (In-House)    
Individual 
impurities. 
Total Impurities. 
NMT 0.2% 
NMT 1.0% 
N.D 
N.D 
0.0% 
0.0% 
0.0% 
0.0% 
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5.8.2 Pregabalin Tablet 75mg (F5, 75) Stability Results 
 
Table 53: Stability results of Pregabalin 75mg @ 25
o
C ± 2
o
C/ 60% RH± 5% RH 
Characteristics Acceptance Criteria @ initial time After 14 days After 30 days 
Appearance 
Oblong white tablet, Characteristic 
Odor with smooth and 
homogeneous coating 
Conform 
Conform Conform 
Length 
Width 
10.1 ± 0.2 mm 
5.1  ± 0.2 mm 
10.1 
5.1 
- 
- 
- 
- 
Thickness 
4.2 (+/- 0.2) mm 
 
3.2 
- - 
Hardness 6.0-12.0 Kgf  
10.1 
9.5 10.1 
Friability NMT 1.0%, 100 rounds 
0.2% 
- - 
Dissolution Test Ref. (In-House)    
Pregabalin 
Not Less than 75.0 % (Q) of the 
labeled amount of Pregabalin  is 
dissolved within 30 minutes 
100.0% 
98.7% 99.8% 
Assay Ref. (In-House)    
Pregabalin 90.0-110.0 %                          
99.0% 
103.4% 101.2% 
Related 
Substances 
Ref. (In-House)    
Individual 
impurities. 
Total Impurities. 
NMT 0.2% 
NMT 1.0% 
0.0% 
0.0% 
0.0% 
0.0% 
0.0% 
0.0% 
 
Table 54: Stability results of Pregabalin 75mg @ 30
o
C ± 2
o
C/ 65% RH± 5% RH 
Characteristics Acceptance Criteria @ initial time After 14 days After 30 days 
Appearance 
Oblong white tablet, Characteristic 
Odor with smooth and 
homogeneous coating 
Conform 
Conform Conform 
Length 
Width 
10.1 ± 0.2 mm 
5.1  ± 0.2 mm 
10.1 
5.1 
- 
- 
- 
- 
Thickness 
4.2 (+/- 0.2) mm 
 
3.2 
3.2 3.2 
Hardness 6.0-12.0 Kgf  
10.1 
9.1 9.5 
Friability NMT 1.0%, 100 rounds 
0.2% 
- - 
Dissolution Test Ref. (In-House)    
Pregabalin 
Not Less than 75.0 % (Q) of the 
labeled amount of Pregabalin  is 
dissolved within 30 minutes 
100.0% 
98.9% 100.7% 
Assay Ref. (In-House)    
Pregabalin 90.0-110.0 %                          
99.0% 
102.3% 101.0% 
Related 
Substances 
Ref. (In-House)    
Individual 
impurities. 
Total Impurities. 
NMT 0.2% 
NMT 1.0% 
0.0% 
0.0% 
0.0% 
0.0% 
0.0% 
0.0% 
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Table 55: Stability results of Pregabalin 75mg @ 40
o
C ± 2
o
C/ 75RH± 5% RH 
Characteristics Acceptance Criteria @ initial time After 14 days After 30 days 
Appearance 
Oblong white tablet, Characteristic 
Odor with smooth and 
homogeneous coating 
Conform Conform Conform 
Length 10.1 ± 0.2 mm 10.1 - - 
Width 5.1  ± 0.2 mm 5.1 - - 
Thickness 4.2 (+/- 0.2) mm 3.2 - - 
Hardness 6.0-12.0 Kgf  10.1 10.5 9.7 
Friability NMT 1.0%, 100 rounds 0.2% - - 
Dissolution Test Ref. (In-House)    
Pregabalin 
Not Less than 75.0 % (Q) of the 
labeled amount of Pregabalin  is 
dissolved within 30 minutes 
100.0% 96.0% 96.0% 
Assay Ref. (In-House)    
Pregabalin 90.0-110.0 %                          99.0% 101.7% 101.2% 
Related 
Substances 
Ref. (In-House)    
Individual 
impurities. 
Total Impurities. 
NMT 0.2% 
NMT 1.0% 
0.0% 
0.0% 
0.0% 
0.0% 
0.0% 
0.0% 
 
 
Discussion of Stability Results: 
All stability study results indicate that Pregabalin tablets are stable in terms of Assay, 
Physical properties, dissolution and related substance at all storage conditions during the 
study period.  
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Test Methods Validation (Data and results) 
5.9 Assay and Related Substances Test  
5.9.1 Linearity and Range:  
Different concentrations of Standard solution were prepared covering the range between 
(40%-160%) of the nominal concentration (1.0 mg/ml) required by the procedure for 
determination of Pregabalin in Pregabalin Tablets. Data and results are summarized in Table-
56: 
Table 56: Linearity and Range Data and Results 
Conc. 
% 
Conc. of Pregabalin 
(mg/ml) 
Peak Area 
1 
Peak Area 
2 
Peak Area 
3 
Average RSD 
40% 0.4 397923 398777 405286 400662 1.0% 
60% 0.6 606374 605375 600093 603947 0.6% 
80% 0.8 800873 794467 786968 794103 0.9% 
100% 1.0 995222 999234 1003545 997228 0.3% 
120% 1.2 1194276 1204666 1192104 1197015 0.6% 
140% 1.4 1379232 1379587 1375498 1378106 0.2% 
160% 1.6 1592187 1584304 1578861 1585117 0.4% 
 
Linearity regression analysis demonstrated acceptability of the method for quantitative 
analysis over the corresponding range. Data and results are reported in table-56 and figure-
31 which demonstrate linearity as well over the specified range with a Correlation 
Coefficient (R
2
 = 0.9998), Slope = 982,963.5, and y-Intercept = 10,776.3. Repetitions of 
standard solutions over the range of linearity are precise with RSD less than 1.1% for all 
levels, concentrations over the range are linear with correlation coefficient equal to "R
2
 = 
0.9998", and accurate for all recoveries over the range and are within the limit (100±2%). 
 
Figure 31: Linearity and Rang of Pregabalin 
  
96 
 
5.9.2 Precision (System Repeatability): 
Six replicate injections of the working standard at nominal concentration (1.0 mg/ml) were 
made according to the test method of analysis for determination of Pregabalin in 
Pregabalin Tablets and the relative standard deviation (RSD) of the peak areas was 
calculated for the above replicate injections as illustrated in Table-57: 
Table 57: Precision of Standard Injection Data and Results 
Inj. No. RT Area 
1 6.347 1006350 
2 6.353 1009890 
3 6.347 1008178 
4 6.343 1016541 
5 6.353 1004494 
6 6.373 1007422 
AV 
RSD 
6.353 1008813 
0.4% 
The relative standard deviation (RSD) of the peak areas for replicate injections of the 
working standard solution at nominal concentration was calculated, with referring to the 
data precision table-64, the RSD is about 0.4%, therefore the system is repeatable. 
 
5.9.3 Ruggedness (Intermediate Precision): 
Ruggedness was studied through analysis of nominal standard solution (1.0 mg/ml of 
Pregabalin) under a variation of analyst and analysis days (Matrix Design). Ruggedness data 
and results are illustrated in Table-58: 
Table 58: Ruggedness Data & Results 
 
 
Injection 
No. 
Analysis by Different Analyst on 
Different Days (Matrix Design) 
R.T Area 
I 5.880 1017260 
II 5.870 996929 
III 5.847 1003262 
IV 5.887 1009491 
V 5.847 1007657 
VI 5.897 1002387 
Average 
RSD 
5.871 1006164 
0.7% 
Limit RSD NMT 2.0% 
Ruggedness was studied through analysis of nominal standard solution (1.0 mg/ml of 
Pregabalin) under a variation of analyst & analysis days (Matrix Design). The RSD result is 
about 0.7%, as illustrated in Table-67. All results are within limits (RSD is NMT 2.0%). 
This indicates that the method of analysis is precise within-laboratories variation. 
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5.9.4 Accuracy of the Drug Products: 
Admixture the Synthetic mixture of the drug product components (Placebo: Placebo was 
prepared according to the formulation procedure reported in the production file of 
Pregabalin Tablets) with known amounts of Pregabalin, (80%, 100% & 120%) of the 
nominal concentration (1.0 mg/ml). Three preparations were made for each concentration 
and the recovery was calculated as illustrated in Table-59 
Table 59: Pregabalin Recovery Data & Results for Accuracy of Pregabalin Tablets 
Conc. 
 % 
Concentration  
(mg/ml) 
Samples 
Area  
% Accuracy 
(Recovery) 
Average 
& 
RSD 
Average Area for 80% of Nominal St. Conc.= 802332 
80% 0.8 799789 99.7% 
99.7%  
&  
0.1% 
80% 0.8 799381 99.6% 
80% 0.8 800496 99.8% 
Average Area for 100% of Nominal St. Conc.= 1002818 
100% 
100% 1.0 1008526 100.6% 
100.2%  
& 
0.4% 
100% 1.0 1001277 99.8% 
100% 1.0 1005557 100.3% 
Average Area for 120% of Nominal St. Conc.= 1204265 
120% 
120% 1.2 1206316 100.2% 100.5%  
& 
1.2% 
120% 1.2 1197834 99.5% 
120% 1.2 1203749 101.9% 
Three preparations for each recovery level (80%, 100% & 120%) of nominal concentration 
are prepared and injected into the liquid chromatograph, the recovery percent was calculated 
for Pregabalin as demonstrated in table-65. The recovery results are (99.7%, 100.2% & 
100.5%, respectively) and are within limits (100±2%). 
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5.9.5 Robustness: 
Robustness was studied through variation of method parameters, variation of flow rate to 
1.65 ml/min. instead of 1.50 ml/min., and variation of detection wavelength to 208 nm 
instead of 210 nm. Data and results are illustrated in Tables-60 
Table 60: Robustness Data and results 
Injection 
No. 
Variation in Flow Rate Variation in Detection 
Wavelength 
R.T Area R.T Area 
1 5.453 901066 5.883 1260983 
2 5.470 898267 5.897 1266299 
3 5.500 893574 5.870 1273643 
4 5.490 897677 5.900 1255641 
5 5.467 900116 5.873 1260652 
6 5.513 905936 5.863 1259450 
Average 
SD 
RSD 
5.482 899439 
4103.5 
0.5% 
5.881 1262778 
6327.7 
0.5% 
Limit RSD NMT 2.0% 
Robustness was studied through analysis of nominal standard solution (1.0 mg/ml of 
Pregabalin) under a variation of method parameters (Flow rate and Detection Wavelength). 
The RSD result for analysis under variation of flow rate is about 0.5% and under variation 
of detection wavelength is about 0.5% and are within acceptance criteria (RSD < 2.0%) as 
illustrated in table-66.This indicates that all parameters are within the methods robustness 
range. 
 
 
5.9.6 Specificity: 
Different reagents were added to the nominal standard solution of Pregabalin and Pregabalin 
spiked on the placebo of Pregabalin Tablets, the assay of the main peak (analyte) in each 
stressed solution is calculated according to test method of Pregabalin Tablets against the 
standard solution injected on the same day. The data and results are illustrated in Table-61 
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Table 61: Stability of Pregabalin standard under different stressing conditions 
Av. Area for Pregabalin St.: 990317                                            Initial %: 100% 
Stress Conditions 
Pregabalin Standard 
Pregabalin Std. Spiked on Placebo 
of Pregabalin Tablets 
Area % Area % 
0.5M HCl 940561 95.0% 964391 97.4% 
0.5M NaOH 985254 99.5% 955171 96.5% 
6% H2O2 
470910 47.6% 467481 47.2% 
508525* 51.3%* 437655* 44.2%* 
Heat in Water Bath at 
70C for 1-Hr 
986388 99.6% 983706 99.3% 
31541* 3.2%* 31636* 3.2%* 
*: Total of Degradants 
 
With referring to the stability indicating table-6, it is clear that, Pregabalin is unstable and 
degraded in the presence of 6% Hydrogen peroxide, 0.5M Sodium Hydroxide, 0.5M 
Hydrochloric acid and at elevated temperatures. As illustrated in Table-6. 
Finally, the peak of Pregabalin is clearly separated from other peaks (Degradation Peaks), in all 
cases studied, with a resolution greater than 1.5 as shown in Figure-34 
As a conclusion, the test method is stability -indicating for determination of Pregabalin in 
Pregabalin Tablets. 
 
Figure 32: Stability Chromatogram for Pregabalin when Stressed with H2O2 
 
5.9.7 System Suitability 
Six replicate injections of the standard solution at nominal concentration (1.0 mg/ml of 
Pregabalin) and Six replicate injections of the Pregabalin and its impurity (IV) were made 
according to the test method of analysis for determination of Pregabalin in Pregabalin 
Tablets and the relative standard deviation (RSD) and Relative RT are calculated, 
Asymmetry and Theoretical Plates, Results are tabulated as illustrated in Table-69. 
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Table 62: System Suitability Data & Results 
Inj. 
No. 
Response Area 
(Pregabalin) 
Tailing Factor 
Column 
Efficiency 
Impurity (IV) 
(Relative RT) 
Impurity (IV) 
Resolution 
1 1006350 1.056 9938 1.9 17.6 
2 1009890 1.073 9917 1.9 18.3 
3 1008178 1.069 9938 1.9 17.7 
4 1016541 1.065 9840 1.9 18.0 
5 1004494 1.058 9932 1.9 17.8 
6 1007422 1.061 9951 1.9 17.4 
AV 
RSD 
1008813 
0.4% 
1.064 9919 1.9 17.8 
 
The results of the System Suitability Parameters were calculated automatically by the 
software (EZChrom Elite) of the Lachrom Elite HPLC System.  
 
Relative Standard Deviation (RSD): 
The Relative Standard Deviation of peak area for replicate injections of Pregabalin standard 
is equal to 0.4%. 
 
Column Efficiency 
The column efficiency for Pregabalin peak is about 9919 theoretical plates. 
 
Tailing Factor 
The tailing factor for Pregabalin peak is about 1.1. 
 
Relative retention time (Impurity IV) 
The RRT for Impurity (IV) is about 1.9, as shown in the figure-3. 
 
Resolution (Impurity IV) 
The resolution between Pregabalin API and RS Impurity IV (Lactam) is about 17.8, as 
shown in the next figure. 
 
Figure 33: System Suitability Chromatogram (Pregabalin and RS Impurity IV) 
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5.10 Dissolution test method validation 
5.10.1 Linearity and Range:  
Different concentrations of Standard solution were prepared covering the range between 
(40%-120%) of the nominal concentration (0.3333 mg/ml) required by the procedure for 
determination of Pregabalin in Pregabalin Tablets. Data and results are summarized in 
Table-63: 
Table 63: Linearity and Range Data and Results 
Conc. 
% 
Conc. of 
Pregabalin 
(mg/ml) 
1st 
Area 
2nd 
Area 
3rd 
Area 
Av Area RSD 
40% 0.1333 0.714 0.696 0.71 0.707 1.3% 
60% 0.1999 1.058 1.064 1.06 1.061 0.3% 
80% 0.2666 1.423 1.386 1.396 1.402 1.4% 
100% 0.3333 1.773 1.784 1.794 1.779 0.4% 
120% 0.3999 2.135 2.143 2.142 2.140 0.2% 
150% 0.4999 2.651 2.659 2.649 2.653 0.2% 
 
Standard solutions were prepared over the range (40% to 150%) of the nominal 
concentration (0.3333 mg/ml of Pregabalin). Linearity regression analyses are acceptable of 
the method for quantitative analysis over the corresponding range. Data and results are 
reported in Table-63 and figure-28 which demonstrate linearity as well over the specified 
range with a Correlation Coefficient (R
2
 = 0.999), Slope = 2513.9, and y-Intercept = 11.599. 
Repetions of standard solutions over the range of linearity are precise with RSD less than 
1.0% for all levels, concentrations over the range are linear with correlation coefficient 
equal to "R
2
 = 0.999", and accurate for all recoveries over the range and are within the limit 
(100±5%) 
 
 
Figure 34: Linearity and Rang of Pregabalin  
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5.10.2 Precision (System Repeatability): 
Six replicate readings of the working standard at nominal concentration (0.3333 mg/ml) 
were made according to the test method of analysis for determination of Pregabalin in 
Pregabalin Tablets and the relative standard deviation (RSD) was calculated for the above 
replicate readings as illustrated in Table-64 
Table 64: Precision of solution, Data and Results 
No. RT Response 
1 6.120 1.791 
2 6.120 1.798 
3 6.150 1.804 
4 6.120 1.78 
5 6.120 1.776 
6 6.120 1.78 
AV 
RSD 
6.125 
0.2% 
1.788 
0.6% 
The relative standard deviation (RSD) for replicate readings of the working standard 
solution at nominal concentration was calculated, with refering to the data precision table-
71, the RSD is about 0.6%, therefore the method of analysis is repeatable. 
 
5.10.3 Ruggedness (Intermediate Precision): 
Ruggedness was studied through analysis of nominal standard solution (0.3333 mg/ml of 
Pregabalin) under a variation of analyst and analysis days (Matrix Design). Ruggedness data 
and results are illustrated in Table-65 
 
Table 65: Ruggedness Data & Results 
 
No. 
Analysis by Different Analyst 
on Different Days (Matrix 
Design) 
Area 
1 1.777 
2 1.788 
3 1.784 
4 1.775 
5 1.773 
6 1.759 
Average 
SD 
RSD 
1.776 
0.01 
0.6% 
Limit RSD NMT 5.0% 
 
Ruggedness was studied through analysis of nominal standard solution (0.3333 mg/ml of 
Pregabalin) under a variation of analyst & analysis days (Matrix Design). The RSD result is 
about 0.6%, as illustrated in Table-65. All results are within limits (RSD is NMT 5.0%). 
This indicates that the method of analysis is precise within-laboratories variation. 
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5.10.4 Accuracy of the Drug Products: 
Admixture the Synthetic mixture of the drug product components (Placebo: Placebo was 
prepared according to the formulation procedure reported in the production file of 
Pregabalin Tablets) with known amounts of Pregabalin, (50%, 75% & 100%) of the nominal 
concentration (0.3333mg/ml). One Dissolution run (6-Vessels) was made for each 
concentration and the recovery was calculated as illustrated in Table-66. 
Table 66: Pregabalin Recovery Data & Results for Accuracy of Pregabalin Tablets 
Conc. 
 % 
Concentration  
(mg/ml) 
Samples Area  
% Accuracy 
(Recovery) 
Average 
& RSD 
Average Area for 100% of Nominal St. Conc.= 1.775 
100% 
Vessel-І 0.3333 1.778 100.2% 
100.1%  
&  
0.2% 
Vessel- ІІ 0.3333 1.772 99.8% 
Vessel- ІІІ 0.3333 1.775 100.0% 
Vessel- IV 0.3333 1.776 100.1% 
Vessel- V 0.3333 1.780 100.3% 
Vessel- VI 0.3333 1.777 100.1% 
Average Area for 75% of Nominal St. Conc.= 1.333 
75% 
Vessel-І 0.2500 1.342 100.7% 
100.5%  
& 
0.5% 
Vessel- ІІ 0.2500 1.348 101.2% 
Vessel- ІІІ 0.2500 1.331 99.9% 
Vessel- IV  0.2500 1.337 100.3% 
Vessel- V 0.2500 1.333 100.0% 
Vessel- VI 0.2500 1.347 101.1% 
Average Area for 50% of Nominal St. Conc.= 0.884 
50% 
Vessel-І 0.1666 0.880 99.6% 
100.1%  
& 
0.3% 
Vessel- ІІ 0.1666 0.887 100.4% 
Vessel- ІІІ 0.1666 0.886 100.3% 
Vessel- IV  0.1666 0.888 100.5% 
Vessel- V 0.1666 0.885 100.2% 
Vessel- VI 0.1666 0.882 99.8% 
One Dissolution run (6-Vessels) for each recovery level (50%, 75% & 100%) of nominal 
concentration is performed and analyzed using the Chromatographic HPLC, the recovery 
percent was calculated for each level of Pregabalin as demonstrated in table-66. The 
recovery results are (100.1%, 100.5% & 100.1%, respectively) and are within limits 
(100±5%). 
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5.10.5 Method Conditions Variation 
Robustness was studied through variation of Chromatographic HPLC method parameters 
and dissolution conditions as variation in rotation speed to 48 rpm instead of 50 rpm, 
Detection wavelength to 212nm instead of 210nm and Flow rate 1.6ml/min instead of 
1.5ml/min.  Data and results are illustrated in Tables-67. 
Table 67: Robustness Data and results for Pregabalin: 
No. 
Variation in 
Rotation Speed 
(RPM) 
Variation in 
Flowrate 
Variation in 
Detection 
Wavelength 
Response Area Response Area Response Area 
1 1.782 1.670 1.448 
2 1.774 1.673 1.445 
3 1.767 1.671 1.449 
4 1.773 1.676 1.446 
5 1.775 1.672 1.441 
6 1.770 1.673 1.445 
Avera
ge 
RSD 
1.774 
0.3% 
1.673 
0.1% 
1.446 
0.2% 
Limit RSD NMT 5.0% 
Robustness was studied through analysis of nominal standard solution (0.3333 mg/ml of 
Pregabalin) under variation of HPLC method parameter (Detection Wavelength and Flow 
rate) and under variation of dissolution test condition RPM. The RSD result for analysis 
under variation of RPM is about 0.3%, under variation of detection wavelength is about 
0.2% and under variation of flow rate is about 0.1%, and all results are within acceptance 
criteria (RSD < 5.0%) as illustrated in table-67.This indicates that all parameters are within 
the methods robustness range. 
 
5.10.6 Specificity (Placebo Interference): 
This test is to demonstrate that the results are not unduly affected by placebo 
constituents for that Placebo, Standard and Sample Solution was prepared at nominal 
concentration and the measurements was performed for both the nominal standard 
solution and for placebo solution at 210 nm wavelength for Pregabalin in order to 
calculate the interference percentage of placebo using the following formula: 
Interference % = 100*C*(AP/ASt)*V/L 
Where, 
C: is the concentration, in mg per ml, of the standard 
AP: is the absorbance of the placebo 
A St: is the absorbance of the standard 
V: is the volume, in ml, of the medium 
L: is the label claim, in mg of the product 
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Table 68: Interference Data and results 
Pregabalin Conc. 
(mg/ml) 
A Placebo A St. V L 
Interference 
% 
0.3333 0.008 1.760 900 300 0.45% 
Acceptance Criteria NMT 2% 
 
 
Referring to Table-68, the result of interference is about 0.45% and it is within limits (the 
interference should be NMT 2%). This means that, the interference of placebo on results is 
too low and negligible in comparison with the interference limit.  
 
 
5.10.7 Specificity / Stability of solution: 
Sample solution was prepared by nominal standard solution spiked with placebo of 
Pregabalin Tablets; both of Sample and Standard solutions were studied at freshly prepared 
time, after 3hr and after 24hr, assay of the analyte in each solution are calculated according 
to test method of  Pregabalin Tablets against the freshly prepared standard solution on the 
same time. The data and results are illustrated in Table-69: 
 
Table 69: Stability of Pregabalin standard and Sample of Pregabalin Tablets under 
different test time. 
Freshly STD Stability STD 
Stability STD Spiked 
with Placebo of 
Pregabalin Tablets 
After 3 hr’s 
1.781 1.807 
1.787 
1.758 
1.766 
Average --- 
101.4% 
1.77 
Degree of Stability 99.4% 
After 24 hr’s 
1.786 1.813 
1.790 
1.779 
1.783 
Average --- 
101.5% 
1.784 
Degree of Stability 99.9% 
 
With referring to the stability indicating table-69, it is clear that, the Pregabalin standard and 
Pregabalin spiked with placebo of Pregabalin Tablets are stable after storage at room 
temperature for period of time starting from zero time (freshly prepared) and up to 24hr of 
preparation. 
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Part VI Conclusions and 
Recommendations 
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Conclusions and Recommendations 
Final Conclusion 
Successful attempts were made to formulate new line extension, Pregabalin 300mg and 
75mg tablets by using excipients generally used in pharmaceutical industry and compatible 
with the active pharmaceutical ingredient. This new line extension is expected to be more 
stable, have high capacity of manufacturing and low manufacturing costs.  
The developed Pregabalin tablets are dose weight proportional and proved to be biowaiver 
to the Reference Drug Product (Lyrica Capsules). 
An HPLC assay and dissolution methods using a PDA UV detector were developed and 
validated for the determination of Pregabalin in pharmaceutical dosage forms, such as 
capsules and tablets. The method has been found to be precise, accurate and stability 
indicating, which is suitable for stability testing of Pregabalin capsules and tablets.  
Pregabalin tablets proved to be stable for the period tested at accelerated and long-term 
storage conditions. 
 
Recommendation and future work 
The following are some suggestions concerning future work: 
1. Complete the stability study of trials processed according to selected formulation up 
to 12 months at long term and intermediate storage conditions, and for 6 months at 
accelerated storage conditions. 
 
2. Formula and particle size optimization to improve the flowability, compaction of 
powder mixture blend and performance of highest strength tablets.   
 
3. Scale up the batch size of tablets to lab scale (25,000 units) and pilot scale (100,000 
units) for stability testing according to ICH, FDA and WHO requirements. 
 
4. Biowaiver study using Pilot batch sizes 
 
5. Registration of product locally and in export countries. 
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Abbreviations 
API: Active Pharmaceutical Ingredient 
AR: Analytical Reagent. 
BDL: Below Detection Limit. 
BP: British Pharmacopoeia. 
COA: Certificate of Analysis. 
COA: Certificate of Analysis. 
FDA: Food and Drug Administration. 
FDA: Food and Drug Administration. 
FPP: Finished Pharmaceutical Product. 
FTIR: Foriour Transmitter infrared. 
HCl: Hydrochloric Acid. 
HPLC: High Pressure Liquid Chromatogram. 
IPC: In-Process Control 
IR: Immediate Release. 
M: Molarity. 
N: Normality. 
NLT: Not Less Than. 
NMT: Not More Than. 
OTR: Oxygen Transition Rate. 
R.T: Retention Time. 
R
2
: Linear Regression. 
RP: Reversed Phase. 
RPM: Round per minute. 
RSD: Relative Standard Deviation. 
SD: Standard Deviation.  
STD: Standard 
SUPAC: Scale up and Post Approval Changes. 
USP: United State Pharmacopoeia. 
VAL: Validation. 
WHO: World Health Organization. 
WS: Working Standard.  
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Appendix 1  
COAs of Pregabalin and Excipients 
 
  
  
114 
 
 
 
  
115 
 
 
 
  
116 
 
 
  
117 
 
 
 
  
118 
 
 
 
  
119 
 
 
 
  
120 
 
 
 
  
121 
 
 
  
122 
 
 
  
123 
 
 
Appendix 2 
Compatibility Study FTIR Spectra  
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Appendix 3 
Typical Chromatograms of Stability 
Study 
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Appendix 4 
Typical Chromatograms for 
Biowaiver Study 
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Appendix 5 
Typical Chromatograms for Test 
methods Validation of Pregabalin 
Tablet 
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(neuropathy)
(Lyrica)
(Pregabalin)
(C18, 25cm*4.6mm, 5-
 (phosphate buffer pH6.9:Acetonitrile) 94:6)
(Compatibility Study)
(FTIR)
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(F5)
(PVC-Aluminum)
 (25-45)(60-75)
FDA 
(Biowaiver Study)(
(Lyrica capsules 300mg & 75mg) 
Paddle
(1.2, 4.5, 6.8)
 
